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Abstract

SYNTHESIS AND BIOLOGICAL EVALUATION OF SECOND GENERATION
ANALOGUES OF ANIBAMINE AS NOVEL ANTI-PROSTATE CANCER AGENTS
By Shilpa Singh, MS
A Dissertation submitted in partial fulfillment of the requirements for the degree of Master’s of
in Pharmaceutical Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2012

Major Director: Dr. Yan Zhang
Associate Professor, Department of Medicinal Chemistry

Prostate cancer is the most prevalent non-cutaneous cancer among men. Since the 19th
century when Virchow first introduced the concept of inflammation in cancer,
chemokines and their receptors have garnered a lot of interest. Chemokine receptor
CCR5 has been especially implicated in many disease states and recently found to be
over expressed in prostate cancer cell lines. Anibamine, a natural CCR5 antagonist
discovered in 2004, has been found to have significant anti-prostate cancer activity at

x

micromolar level. To optimize this compound and also discover a novel pharmacophore,
exploration of the original structure was carried out. Significant modifications were made
to the side chain in the original structure and ten different analogues were prepared by
altering the original synthetic route. While cytotoxicity assay proved the compounds to
be non toxic to normal cells, anti-proliferation assay displayed that having a bulky,
hydrophobic group in the side chain of the parent compound is essential for the activity.
Looking at this data, the third generation of analogues can be prepared that might
generate a better lead compound for the treatment of prostate cancer.
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INTRODUCTION

Prostate cancer is currently the most common non-cutaneous neoplasm among
men in Western countries. According to the latest statistics, prostate cancer accounts for
28% of the newly diagnosed cases of cancer in men. There have been approximately
217,730 estimated cases of prostate cancer in the United States and around 32,050
deaths1. Radical prostatectomy or radiation therapy can be used to treat a more localized
prostate cancer. However for more advanced cancers, androgen ablation therapy has
shown beneficial effects only for hormone-responsive disease. Apart from these, there are
new treatment techniques that are still in clinical trials. These include cryosurgery,
chemotherapy, biological therapy etc2. Prostate cancer cells that become hormone
independent also become highly invasive. They reach clinical stage associated with an
increased incidence of skeletal metastases as the disease progresses. Hence, even though
diagnosis techniques for early detection have improved, there has been no cure for men
suffering from advanced stage metastatic prostate carcinoma3.
Since the 19th century there has been increased interest in the role of inflammation
in neoplastic process. Approximately 20% of all human cancers in adults evolve from
chronic inflammatory states and/or chronic inflammation. Prolonged inflammation is
believed to potentiate carcinogenesis by providing a microenvironment that is ideal for
cancer development and proliferation. This environment which is rich in inflammatory
cells, growth factors, activated stroma, and DNA-damage-promoting agents, potentiates
or promotes neoplastic risk. This theory led to studying the involvement of chemokines
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and chemokine receptors in cancer development and progression.

Since the time when

novel aspects of ‘chemokine receptors and cancer metastasis’ were first discussed by
Muller et al., chemokine receptors expressed on cancer cells have been discovered to
play key roles in cancer progression29, 34.
Chemokine receptor CCR5 regulates trafficking and effector functions of
memory/effector T lymphocytes, immature dendritic cells and macrophages. It has been
known to play an important role in pathogenesis of many diseases such as Alzheimer’s,
atherosclerosis, HIV and in certain cancers like breast, prostate and ovarian. Amongst all
these, it’s most extensively researched role is that of a co-receptor along with CXCR4
for the entry of R5 strains of Human Immunodeficiency Virus (HIV-1, HIV-2) into the
cell. Apart from their use as anti-HIV agents, CCR5 antagonists have also been studied as
potential anti- prostate cancer agent. This theory is supported by the fact that CCR5 is
found to be over expressed in prostate tumor cells and its substrate CCL5 binds to the
receptors on PCa cells to activate cellular responses that are vital to cancer progression7.
Anibamine, the first and only natural CCR5 antagonist was found to successfully
inhibit proliferation of prostate cancer cell lines in in-vivo studies at micro molar level. It
was successfully synthesized in our lab recently. However due to its poor bioavailability,
high log P values and hemolytic tendencies, it proved to be a less ideal drug candidate.
Despite that it provided us with a novel structural skeleton compared to other CCR5
antagonists identified through high-throughput screenings carried out by research groups
in search for anti-HIV agents8.
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The main goal of this project was to design second generation compounds having
structural features of anibamine through “Deconstruction-Reconstruction-Elaboration”
approach and to evaluate their biological activity. These analogues were designed in a
way to establish a suitable structure-activity relationship and also to verify a novel
pharmacophore. The reconstructed analogues were synthesized through two different
routes. These newly synthesized antagonists were then tested for their anti-proliferative
activity, cytotoxicity and calcium mobilization inhibition ability against PC-3, DU-145
and M12 cell lines. This research may possibly lead to discovery of a clinically relevant
CCR5 antagonist.
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2. BACKGROUND
2.1 Prostate Carcinoma
2.1.1 Prostate Gland
The word prostate has originated from the Greek word prostates meaning
“guardian”. It is a donut shaped excretory organ unique to male physiology. It is located
below the urinary bladder and surrounds urethra. It weighs about 25g and is size of a
walnut on complete maturation. It serves the dual function of an accessory sex gland and
a urethral gland. Secretions of epithelial cells empty via ducts into urethra forming a vital
part of the seminal ejaculate. This alkaline secretion which is milky white in color
constitutes 20-30% of the ejaculate. The smooth muscles of the prostate also aid in
expulsion of the semen and it has a fibromuscular function to restrict urine flow4.
Prostate attains its complete mature size and function by the age of 18-20 years
and retains this organization for about 10 years. The growth of prostate and its
maintenance is stimulated by serum testosterone. In simplest terms, testosterone enters
the cell by facilitated diffusion where it is converted to dihydrotestosterone (DHT). DHT
from there on binds to cytoplasmic androgen receptor and this hormone-receptor complex
undergoes transformation and translocation to the nucleus. This causes activation of RNA
polymerase and leads to synthesis of specific protein enzymes in the ribosome.

Other

than testosterone, adrenal androgens and certain growth factors are also responsible for
its normal function and size preservation5, 6.
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At about 30 years of age, the structure and function of prostate begin to
deteriorate. At this point the stromal and parenchymal cells are dormant with respect to
proliferation. At the age of 45-50 years, due to changed hormonal conditions, the
proliferative activity of the cells recommence under strict regulatory conditions7.
The human prostate can be divided into three zones; the transition zone, the
peripheral zone and the central zone. About 80% of the prostate cancers and prostate
inflammation called prostatitis have been known to originate in the peripheral zone which
lies to the rear of the prostate. The most common prostate proliferative disorder called
Benign Prostate Hyperplasia (BPH) is known to originate in the transition zone which is
located in the middle of the prostate and surrounds the urethra8. The prostatic epithelium
can be divided into 3 different types of cell populations; secretory luminal cells, basal
cells and the endocrine-paracrine (EP) cells. The three types of cells are known to differ
markedly in their marker expression and hormonal regulation. The luminal cells are the
functionally active cells responsible for synthesizing the secretory products that form part
of the semen. They are highly differentiated and express androgen receptors (AR). They
also synthesize prostate-specific antigen (PSA), a protein that acts as a marker for
prostate cancer detection and to monitor its progress. In contrast the basal cell layer is
highly undifferentiated and is known to be androgen-independent. In fact they express
nuclear receptors for estrogen and progesterone but lack AR9.
A. Prostatic Disorders
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There are various problems associated with the prostate. As mentioned before,
there is prostate cancer and prostitis that originate in the peripheral zone. Several studies
have been performed to establish a relationship between the two. However, due to certain
case study biases it has been difficult to validate this relationship. Nevertheless, an
increased risk of prostate cancer has been found in men with a history of prostatis. There
are four different categories of prostatitis recognized by NIH and only first three have
been focused on to study the correlation between prostate cancer and prostatis10. Another
common finding in the periphery of the prostate gland is proliferative inflammatory
atrophy (PIA). These are mainly used to describe foci of inflammation with proliferative
epithelial cells. PIA represents various morphologically diverging glandular structures
ranging from simple atrophy, post-atrophic dysplasia to sclerotic atrophy. There have
been reports suggesting the role of PIA as a cancer precursor11. They originate in the
peripheral zone where PCa is known to originate and are also known to share some of the
genetic characteristics with the PCa12, 13, 14. Also many groups have suggested a paradigm
to explain the relationship between PCa and PIA10, 15. According to the proposed model,
these atrophic lesion arise from normal epithelial cells due to genotoxic injury caused by
inflammation (generation of reactive oxygen and nitrogen species), infection,
environmental toxins (e.g. from diet) or combinations of these. The injury causes body to
initiate the regenerative response in order to repair the damaged cells. These regenerative
lesions have the morphological appearance of focal atrophy. If the genotoxic insult
continues and if the individual PIA regions are unable to defend themselves against
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genomic damage, they may progress to prostatic intraepithelial neoplasia (PIN) or even
PCa. PIA may directly progress to PCa or go through the step of high grade PIN lesions
formation. PIN lesions are putative precursors of PCa16.
Other than the aforementioned abnormalities that originate in the peripheral zone,
there are certain disorders that stem from transition zone, such as, benign prostatic
hyperplasia (BPH) and atypical adenomatous hyperplasia (AAH). With increasing age,
hormonal imbalance between estrogen and androgen action causes BPH. Studies have
shown decreased dihydrotestosterone and 5 alpha-reductase activity in the epithelium and
an increase in estrogen levels in the prostatic stroma. This is mainly caused by a
discrepancy between cellular proliferation and apoptosis17, 18, 19. BPH usually manifest as
small nodules at its inception, eventually proliferating and increasing the size of the
gland. There is an abnormal increase in the smooth muscle tone of the prostate causing
urethral obstruction. BPH is often erroneously confused with PCa. It is non malignant
and is more of a differentiation abnormality rather than irregular epithelial proliferation.
AAH is a hyperplastic lesion lacking significant nuclear atypia. It is localized to basal
cell layer in the transition zone and like PIN lesions it may serve to act as a PCa
precursor20.
2.1.2 Prostate Cancer Cell Lines
Effort to generate suitable in vitro prostate cancer models dates back to almost
half a century ago. It began with the pioneering work of Burrows et al leading to
generation of the best studied and readily available immortalized prostate cancer cell
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lines. Their use has contributed greatly to our understanding of prostate carcinogenesis
and its progression21. Because of this better understanding, using recombinant DNA
technology new cell lines have been developed in the past 2-3 years. Immortalized cells
have been generated that can not only maintain expression of differentiation, but also
have unlimited lifespan making them suitable to use as standardized cell models. They
can help us study the anti proliferative, anti metastasis and anti invasive properties of
cancers22, 23.
The three prostate cancer lines used in this project are PC-3, DU-145 and M12.
PC-3 cell line was obtained from lumbar vertebra of a 62-year old male Caucasian in
1979. PC-3 cells were initially found to not express PSA and were also stated to be AR (). However recent studies show that they express detectable levels of AR mRNA and also
show positive staining for PSA24,

25

. PC-3 cells have shown to express high levels of

TGF-α mRNA and EGF-R mRNA which probably contributes to their autonomous
growth. They also show increased expression of transferrin. PC-3 cells also express high
affinity for TGF-β receptors and secrete TGF-β into the culture media. Exogenous TGF-β
initially inhibits the anchorage independency and growth of the cells. But prolonged
exposure causes the growth to become normal again24.
DU-145 cell line was obtained from a tumor removed from metastatic central
nervous system lesion of a 69-year old Caucasian male in 1975. The doubling time of
these cells is about 34 hours. As with PC-3, DU-145 has also shown mixed reports on
hormone dependency and PSA expression. They express high amounts of TGF-α and
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EGF receptors that are involved in the autonomous control of their proliferation. A study
showed amplified TGF-α gene in these cells. Increased expression of transferrin similar
to PC-3 has been reported. They also express high amounts of insulin-like growth factor
receptors and secrete IGF-1 into the media that stimulates their growth. Increased
production

of

these

autocrine

growth

factors

could

explain

the

androgen

unresponsiveness of these cells24, 25.
M12 cell line was derived from parental P69SV40T cell line. Parental P69 cell
line was created by immortalization of non-neoplastic prostate epithelial cells through
transfection using an SV40 construct. Their tumorigenicity was assessed by
subcutaneously injecting cells into nude mice and monitoring the tumor growth. 2 out of
18 mice showed presence of tumors after a latency period of 6 months. Cells from these
mice were isolated in-vitro and re-injected three more times in athymic nude mice. All
the mice injected with the sublines developed progressively growing tumors, however,
none that were injected subcutaneously showed metastases. When M12 subline was
injected directly into mouse prostate it produced tumors in all of the mice and showed
extensive metastasis in lungs and diaphragm of these animals. These results are in direct
contrast with the parental P69 cell line behavior which showed zero metastatic capability.
Also the tumorigenic and metastatic capacity of M12 remained when cultured in-vitro26,
27, 28

.
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DU-145

PC-3

M12

ANDROGEN
RECEPTOR

?

?

-

PSA EXPRESSION

-

?

-

EGF STIMULATION

+/-

-

+

TGF-β INHIBITION

+

+

NR

TUMORIGENECITY
IN

+

+

+

BRAIN

VERTEBRAE

PROSTATE

NUDE MICE

DERIVATIVES
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TABLE1: Comparison between different prostate cancer cell lines. +(positive); (negative); +/-(low response); NR(not reported)24, 25, 26,27,28.

2.2 Inflammation and Cancer
About one and a half centuries ago Rudolph Virchow put forth a theory linking
inflammation with cancer. He noticed presence of white blood cells in neoplastic tissue
and made the connection, suggesting that cancer originated at sites of chronic
inflammation29. Studies performed to explain this link proves to us that, when normal
cells undergo tissue injury due to a wound, they begin cell proliferation to regenerate the
damaged tissue. Once the assaulting agent is removed, proliferation and inflammation
subside completing the repair. However, in tissue with damaged DNA or those suffering
from mutagenic assault, the cells continue to proliferate in an environment rich in
inflammatory cells and growth factors which further support their growth. Hence to put it
in simple words, tumors behave as wounds that fail to completely heal30.
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Immune system of the body can be divided into innate and adaptive immune
response31,

32

. An inflammatory response could be initiated via antigen-dependent or

antigen-independent stimulation. Antigen-dependent response leads to T-cells activation
along with the help of T-cell receptors (TCR) which forms the adaptive immune system.
Antigen-independent response involves the activation of key players of innate immune
system – granulocytes, macrophages, dendritic cells, natural killer cells and mast cells.
Also the inflammatory response can be divided into acute and chronic. Acute
inflammation is a short lived process. Chronic inflammation on the other hand is a
prolonged response due to the persistence of the causative stimuli. It could last for weeks,
months or also indefinite time. This eventually causes tissue damage and is followed by
healing and repair process33.
Normal tissue has a very organized and segregated architecture compared to
cancerous tissue as depicted in Figure 134. Epithelial cells sit on a platform of basement
membrane separated by dermis that has a well organized vasculature. On receiving
wounds, platelets are activated leading to a series of events that helps in fibrin clot
formation. Chemotactic factors are released that assist in extracellular matrix remodeling.
Also epithelial cells and stromal cells participate in a reciprocal signaling to facilitate
healing and once the wound is healed, this is suspended. In contrast invasive carcinomas
are more chaotic in their structural design. The neoplasia-associated angiogenesis gives
rise to a very poorly organized vasculature, lymphatics, and remodeled matrix to facilitate
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invasion. Also many reciprocal signaling occurs simultaneously. The inflammatory cells
and the cytokines released by them function to favor neoplastic spread and metastasis34.
Chronic inflammation has the ability to directly alter the nature of the normal
cells either by altering their genetic makeup (especially of the genes responsible for
growth), or by providing the necessary trigger for uncontrolled growth in the cells that
are already modified. Triggers that cause chronic inflammation leading to cancer include,
microbial infections such as Helicobacter Pyroli, autoimmune diseases such as
inflammatory bowel disease, and other inflammatory conditions of unknown origin like
prostatitis. Inflammatory disorders such as gastritis, hepatitis, esophagitis caused by
bacteria, virus, and also physical factors like heat, cold, smoke etc. are risk factors for
cancer35, 36.
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Epithelial cells and basement membrane
Neutrophils
Macrophage/monocyte

Endothelial cells and capillary support cells
Mast cells/eosinophils/basophils
Fibroblast and fibrillar collagens

Platelets and fibrin clot
Cytokines/chemokines
Fibroblast and fibrillar collagens

Figure 1: (a) Normal tissue wound healing versus (b) tumor growth in damaged tissue34.
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2.3 Tumor Microenvironment
Right from discovering presence of leucocytes for the first time in neoplastic
tissue, to today, understanding of the link between inflammation and cancer has helped
shed a lot of light on cancer prevention therapy development. Tumor cells are known to
produce various cytokines that can attract leukocytes. A developing neoplasm has an
environment rich in leukocyte population such as, neutrophils, dendritic cells,
macrophages, eosinophils, mast cells, lymphocytes, etc. All of these cells are capable of
producing various cytokines, reactive oxygen species, interferons (INF), TNF-α,
interleukins, proteases, and MMPs29,

34

. Tumor-associated macrophages (TAM) are an

important component of the inflammation system of a tumor. They are derived from
circulating monocyte precursors, and are lead to tumor via monocyte chemotactic protein
(MCP) chemokines. TAM have two contradictory roles. When activated by IL-2, IL-12
and interferons, they kill neoplastic cells and initiate tissue destructive responses. But on
the other hand, they produce potent angiogenic and lymphangiogenic growth factors and
cytokines which could potentiate tumor growth. They also produce IL-10 that negates the
anti-tumor response of the cytotoxic T-cells37, 38.
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FIGURE 2: Inflammation in Cancer-Macrophages that are present in the tumor
microenvironment produce factors such as MMP, TGF-β, VEGF, RNS, ROS, TNF-α,
and interleukins. These factors cause stromal remodeling and angiogenesis at the tumor
site. They also cause mutagenesis of the tumor epithelial cells and down-regulate
apoptotic pathways, leading to mutagenesis. The end result of stromal remodeling,
angiogenesis, and mutagenesis is carcinogenesis and tumor growth progression39.
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Dendritic cells (DC) play an important role in forming a link between innate and
adaptive immunity. They migrate to inflamed peripheral tissue to capture antigens and
and on maturation activate T-cells. Tumor associated dendritic cells (TADC) have an
immature phenotype with defective ability to stimulate T-cells. They are poor inducers
of effective responses to tumor antigens proved by the fact that they are found at the
invasive edge of the tumor40.
Most of the larger granular lymphocytes are natural killer cells which are rarely
found in a tumor microenvironment. Out of small lymphocytes, T-cells contribute to the
tumor microenvironment. Tumor infiltrating T-cells produce a repertoire of cytokines
including IL-4 and IL-5. Signaling of the T-cell receptor is defective in TIL, making Tcells ineffective against tumors and viruses34.

2.3.1 Chemokines
Cytokines are small signaling molecules that are secreted by numerous cells of the
immune system and are used extensively in intercellular communication. Through
cytokine receptors expressed on target cells, they can modulate function and behavior of
cells at picomolar and nanomolar concentrations. They function by inducing other
cytokines through cascade-like activity, transmodulating cytokine cell surface receptors
or by interacting synergistically, additively or antagonistically on cell functions. They can
be divided into interleukins (IL-1α, IL-1β, IL-2), the chemokines (IL-8, MCP-1),
interferons (IFN-α, IFN-β, IFN-γ), cytotoxic, immunomodulatory growth factors (TNF-β,
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TNF-α, TGF-β) and colony-stimulating factors (G-CSF, IL-3)41. Chemokines are a family
of small 70-130 amino acids cytokines, or proteins secreted by cells. They have ability to
induce directed chemotaxis in nearby responsive cells that is they are chemotactic
cytokines. These proteins activate G-protein coupled receptors and through concentration
gradient, induce the cells to accumulate at the site of chemokine production. Some
chemokines are produced by cells during an infection or as an pro-inflammatory
stimulus. These inflammatory chemokines cause the migration of leukocytes to the
injured site, initiate an immune response and begin wound repair. Chemokines initiate the
response via a two step process. In the first step it recognizes and binds specifically to the
receptor. This is followed by conformational change in the chemokine in the second step.
The conformational change in the chemokine is mainly due to the large flexible N
terminus, and this allows the N terminus to make the necessary interactions with the
receptor which leads to its activation. After the activation, bound GDP is exchanged for
GTP in the α subunit of the G proteins. The G protein then dissociates from the receptor
and activates several downstream effector molecules, which causes a cascade of signaling
events within the cytoplasm. The result of this process is many physiological changes
such as leukocyte migration and trafficking, cell differentiation, angiogenesis and
leukocyte degranulation42.
Chemokines can be sub divided into four families based on the pattern of four
invariant cysteine residues that form disulfide bonds. These are found in the N terminus.
Covalent bonds are formed between the first and third and also between second and
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fourth residues. The four main classes are termed as CC, CXC, CX3C, C based on the
number and spacing of conserved cysteine residues. Most of the chemokines are divided
between CC and CXC. When there is an intervening amino acid between the first two
cysteine residues it’s termed as CXC or α-chemokines. If the two cysteine residues are
adjacent then it’s called CC or β-chemokines. CX3C or γ-chemokines has only one
chemokine in its family and has three amino acid residues between the first two
cysteines. CX3C chemokine is unusual in that it is part of a cell surface receptor. In C or
δ-chemokines, there are only two of the four cysteines. There is a remarkable redundancy
in chemokine, with multiple chemokines binding to the same receptor and multiple
receptors binding the same chemokine43. Chemokines can also be classified as inducible
or constitutive. Inducible chemokines are induced by inflammatory stimuli and hence
control the leukocyte infiltration into the inflamed area. Constitutive chemokines are
mainly involved in housekeeping functions in hematopoiesis in embryo and also
homeostatic leukocyte movement in an immune response. Other than this, CXC
chemokines can be classified as ELR+ or ELR- depending on presence or absence of
‘glu-leu-arg’ motif44.
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FIGURE 3: Classification of chemokines48

One of the earliest findings of chemokine involvement in cancer was that of
endogenously produced human interleukin (IL-8), which acted as a growth factor for
melanoma cells of human45, 46. As seen before tumors contain inflammatory cells like
neutrophils, macrophages and lymphocytes. These inflammatory cells, tumor cells, and
stromal cells contribute to the chemokine setting at the tumor site thereby regulating the
influx of leukocytes that subsequently occurs47. CC chemokines are known to be the chief
contributors to lymphocyte and macrophage infiltration in melanoma carcinoma of
cervix, breast, ovary and also certain sarcomas29. Invasion and metastasis of cancer cells
has been known to be associated with tumor-derived serine proteases and
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metalloproteinase. Tumor cells produce and secrete lytic enzymes called proteases that
have the ability to penetrate through tissues. Many chemokines are selectively cleaved by
certain membrane bound soluble proteases. As a matter of fact, precursor plasma
chemokines like CXCL7 and CXCL14 require proteolytic cleavage in order to attain
receptor affinity. Lymphocyte migration towards CCL5 and CCL4 ligands is also brought
on by cleavage. Other than this, those chemokines, like CCL2, CCL7 and CCL8, with
monocyte attracting capability, have impaired capacity to attract TAM when their Nterminus is cleaved and function instead as receptor antagonist for intact CC chemokines.
Proteolytic cleavage and its effect on cancer invasion and metastasis still needs to be
studied more extensively in vivo49, 50.
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FIGURE 4: Role of chemokines in the tumor-specific immune response. The
type and the amount of the chemokines secreted by tumor and inflammatory cells
determine the extent and the effect of immune response leading to antitumor cytotoxic
response, limited inflammatory, and vascular activation or potentiating tumor cell
proliferation and neoangiogenesis51.
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Understanding role of chemokines in cancer progression and growth is a complex
process. They are known to be involved in almost all steps of tumor growth, right from
invasion to metastasis to distant organs. As BPH progresses to PCa, various chemokines
and their receptors show alteration in their expression51. Murphy et. al. in 2005 revealed
that CXCL8 is weakly expressed at the apical membrane of epithelial cells52. Studies of
BPH have shown that levels of pro-angiogenic CXCL8 are higher in BPH as compared to
normal prostate. This is verified by the presence of increased myofibroblasts in the
stroma of BPH53. CXCL1 is found to be lower in BPH as compared to normal prostate
but, angiostatic chemokines CXCL1 and CXCL11 are found to be more abundant in
comparison54

,55

. Cell lines like DU-145 and PC-3 confirm high levels of CXCL1,

CXCL3, CXCL5 and CXCL656, 57, 58. Levels of CXCL14 are also know to increase with
Gleason score59. A large amount of work has also been put into study of CXCL12 and its
receptor. Expression levels of CXCL12 are higher in PCa tissue in comparison with BPH.
It is known to be associated with perineural invasion of prostate cancer60.
CCL5 also known as RANTES (Regulated upon Activation Normal T cell
Expressed and Secreted) is a small protein of 68 amino acids. It is known to bind CCR1,
CCR3, CCR4 and CCR5) and cause leukocyte migration. It regulates the movement of T
cells, monocytes, basophils, eosinophils, natural killer cells, dendritic cells and mast
cells. It is generated chiefly by CD8+T cells, epithelial cells, fibroblasts and platelets. It
has particularly attracted a lot of attention for its role in HIV entry into host cell. It plays
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a key role in the body’s immune response to viral infection. Increased RANTES
expression has been associated with different kinds of inflammatory disorders like
atherosclerosis, asthma, atopic dermatitis and also neurological disorders like
Alzheimer’s disease61. It has also been indicated in various types of carcinomas. When
RANTES was transduced into tumor cells, it stimulated host immune response and
consistently induced decreased tumorigenicity. It also activates apoptotic pathway in T
cells which leads to cell death. Contradictorily, it has been known to be involved in
increased chemotactic response of breast cancer cell lines62. Also a recent studied showed
that, a chemokine receptor antagonist of the CCL5 receptors CCR5 and CCR1 was shown
experimentally to inhibit breast tumor growth, further implicating CCL563. Studies
performed by Konig et. al. verified 67% and 89% expression of CCL5 and CCR5 mRNA
respectively in PCa specimens64. Further studies demonstrated that chemokine CCL5
may function as an autocrine factor binding to the cell surface receptors of PCa cell lines
thereby activating chain of reactions that could lead to cancer progression65.

2.3.2 Chemokine receptors
Chemokine receptors belong to the G protein-coupled receptor (GPCR)
superfamily and according to the type of chemokines with which they interact are
classified as CC, CXC and CX3C. Apart from this traditional nomenclature, they can also
be classified as inducible or constitutive depending on its function. Their activation leads
to formation of intracellular signaling cascade that cause the movement toward
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chemokine source. They have seven trans-membrane spanning helices connected by
extra membranous loops66. Till date twenty chemokine receptors have been identified67.
Out of these ten are highly selective for a specific endogenous ligand. Rest of them are
known to be more promiscuous and have the ability to bind to different chemokines.
Unlike other types of GPCRs they tend to have overlapping specificities. For example,
CCR5 has the ability to bind to CCL3, CCL4 and CCL5. Hence many chemokinechemokine receptor-mediated signals are redundant while others are indispensable68.
Chemokine receptors are embedded in the lipid bilayer of the cell surface. They
are composed of 350 amino acids and weight approximately 40 kDa69. No chemokine
receptor structures have been solved to date. Most of the models are based generally on
bovine rhodopsin, the only 7TM receptor for which three dimensional structures are
available70, 71, 72. The signal transduction mechanism of these receptors involve coupling
to heterotrimeric G-proteins bound to the intracellular loop. The Gα subunit directly
interacts with the intracellular loop of the receptor and the Gβ subunit which in turn
interacts with the Gδ subunit. Gα contains a GTPase which is responsible for hydrolysis
of GTP. In inactive state of the receptor Gα subunit is bound to GDP. When a ligand
binds to the receptor, it causes certain conformational changes which leads to dissociation
of GDP from Gα subunit and replacement with GTP instead. This Gα-GTP complex
dissociates from the receptor and Gβδ heterodimer complex. The two complexes go on to
activate downstream effectors that ultimately brings out the desired physiological change.
Continuous stimuli lead to receptor internalization and desensitization via agonist-
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dependent phosphorylation of the C-terminus of the receptor. When the receptor is
phosphorylated it encourages arrestin binding, which sterically hinders further interaction
with G proteins73, 74, 75.

FIGURE 5: Chemokine receptor signaling pathway65.
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The steps by which tumors grow and metastasize includes, growth and survival of
the primary tumor, detachment from the primary lesion, invasion into vascular and
lymphatic vessels, adherence to distant target organs, and finally survival, growth and
organogenesis of the metastasized cells in their new environment. These are all very
complex steps. It is important for cancer cells to derive and provide signals to shape a
propitious microenvironment especially because alternate environments, like bone
marrow and lymph node are not naturally compatible with cells from other organs such as
prostate. To assist with these processes, chemokine receptors and their corresponding
chemokines provide directional prompting for migration, help with providing a suitable
microenvironment and providing survival and growth signals77,

78

. One important

difference between normal cells and cancer cells is the aberrant expression of certain
chemokine receptors compared to their normal counterparts. For instance, CXC4 was
found to be strongly expressed in breast carcinoma when compared with normal breast
epithelial cells, which do not express it at all. CXCR4 has also been implicated in 23
other cancers. Prostate cancer cells are found to express CXCR4, CXCR5, CCR9,
CX3CR1 and CCR579, 80, 81.
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A chemokine that is generating a lot of interest among researchers, for prostate
cancer treatment development is the CC chemokine receptor CCR5. It is being widely
studied due to its implications in various diseases states. It is over expressed in breast as
well as prostate cancer tissues. Other than that, it is also expressed on human CD4+ T
cells and is therefore an important requisite for human immunodeficiency virus (HIV)
entry into host cell. Because this and several other implications it has been accepted as an
important therapeutic target.

2.4 CCR5
2.4.1 Structure and Signaling
CCR5 was first identified in 199682. CCR5 belongs to the seven transmembranespanning (7 TMS) receptors that signal through G proteins. Its expressed on resting Tlymphocytes, monocytes, macrophages, and immature dendritic cells83. It’s made of 352
amino acids and weighs approximately 40.6 kDa. It also shares 71% sequence identity
with CCR2, with majority of the differences located on the extracellular and cytoplasmic
domains84, 85. Similar to other chemokine receptors, it has four cysteine residues in all
four extracellular domains, a conserved DRYLAVHA sequence in the second
intracellular loop which has been implicated in G protein interaction. MIP-1α (CCL3),
MIP-1β (CCL4) and RANTES (CCL5) are some of the known endogenous ligands to
CCR5. Other than these, monocyte chemo attractant protein-2 (CCL8) and MCP-4
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(CCL13) also show reasonable activity towards CCR5. CCR5 is involved in migration,
chemotaxis, cellular shape changes, metastasis, degranulation, and ROS production23.
A model proposed to explain the mechanism of activation of the receptor
describes two main steps. First step involves an initial interaction between the chemokine
core and the exposed amino terminal receptor domain along with an association with the
adjacent to the second extra cellular loop of CCR5. In the second step, free amino
terminal domain of the chemokine interacts with the transmembrane helix bundle thereby
triggering receptor activation86.
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FIGURE 6: Two dimensional schematic representation of CCR5 receptor86.

As shown in Figure 6, the receptor has a disulfide bond between two conserved
cysteine residues on the second and third extracellular loop. There are two additional
cysteine residues that form a disulfide bridge between the N-terminus and the third
extracellular loop. These bridges impose a steric constraint on the receptor and hence
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stabilize the conformation which is capable of ligand binding. The exact way in which
chemokines interact with and activate CCR5 is not yet known. However, a study
performed by Blanpain et. al. showed that second extracellular loop and amino terminal
domain of CCR5 are essential for chemokine binding. The transmembrane helix on the
other hand is involved in receptor activation. N terminus of CCR5 mediates receptor
activation by interacting with the transmembrane receptor helix bundle whereas, the core
domain of RANTES binds with distinct residues on extracellular loop domains of the
receptor86.
We all know that chemokine receptor activities are mediated through pertussissensitive heterotrimeric G proteins. The αi subunit and βγ dimers of G proteins regulate
downstream effectors, such as adenylyl cyclase or phospolipase C that causes CCR5mediated intracellular calcium mobilization and also inositol-1,4,5-triphosphate (InsP3)
formation87,

88

. Activation of phospholipase C (PLC) via CCR5 leads to formation of

diacyl glycerol and activation of phosphokinase C (PKC). PKC in turn causes receptor
phosphorylation and helps in counter regulating the receptor activation89. CCR5 ligands
also activate three main members of mitogen activated protein (MAP) family – ERK1/2,
p38 and SAK/JNK. These are known to be important for T cell proliferation and
transcriptional activation of cytokine genes90.
CCR5 has been implicated in many diseases and conditions. It is treated as an
important therapeutic target. Some of the CCR5 related diseases include breast cancer,
prostate cancer, AIDS, neuropathic pain, multiple sclerosis, rheumatoid arthritis,
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autoimmune diabetes, Alzheimer’s disease, wound healing, chronic inflammatory
disease, asthma etc. Out of all of these its role in cancer and AIDS are most highly
researched.
2.4.2 CCR5 and HIV
The retrovirus HIV-1 or human immunodeficiency virus has been known to cause
AIDS (Acquired immunodeficiency syndrome). It was first identified in United States
almost three decades ago in 1981. It has been estimated that almost 2.7 million people get
affected by this syndrome every year and almost 33 million are currently living with it.
Majority of the population inflicted with this disease comprises of women91.
Current anti-retroviral therapy (ART) comprises mainly of inhibitors targeting
enzymes such as protease inhibitors and reverse transcriptase inhibitor. However, due to
problems such as development of resistance, transmission of resistant virus, complication
with application and toxicity of current regimen, there has been increased demand in
developing better and much more effective therapy. A new promising target for the
therapy that is being extensively researched is the viral mode of entry into the host cell
and integration of the viral DNA into human genome. Being a novel target it shows great
prospective in being active against resistant viruses as well92.
The ingress of virus into the host cell is a complicated multi step process requiring
several conformational rearrangements and extremely specific interations between the
viral envelope and cellular surface receptors. Viral entry into host can be explained in
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four steps – attachment, CD4 binding, co-receptor binding, and membrane fusion. Each
of the four steps can be suitable targets for anti-HIV intervention. CCR5 acts mainly as
an attachment inhibitor along with CXCR4. Viral envelope gp120 protein of HIV-1
interacts with CCR5, whereby CCR5 acts as co-receptor for its entry. The protein gp120
binds to the CD4 receptor on T-cells and macrophages to start the infection process.
Binding with to the CD4 receptor brings about a conformational change in the gp120
protein and allows it to bind a second receptor on the host cell. Amongst these essential
co-receptors are CCR5 and/or CXCR4. Binding to these receptors brings about a second
conformational change in the HIV envelope of gp41 protein. This ends up revealing a
peptide that fuses the HIV envelope to the host cell membrane allowing for viral
transmission. Viral envelope protein gp120 therefore acts as a high affinity ligand for the
CCR5 receptor and hence both CCR5 and CXCR4 can be potential targets for antiretroviral therapy93.
As mentioned earlier virus uses CCR5 and/or CXCR4 to interact with gp120. While all
HIV-1 isolates require atleast CD4 to enter and infect, some use CCR5 and are called R5
tropic strains, others use CXCR4 and are known as X4 tropic strains. Still some can use
either of the two receptors and are designated R5X4 strains94. The R5 strains are
imperative for the person-to-person transmission of HIV and maintenance of infection,
proving to us that CCR5 has a very critical role in vivo. Those individuals, that do not
express CCR5 on the surface of their cells due to mutations like base pair deletions, are
found to be highly resistant to HIV infection. R5X4 and X4 strains tend to then arise later
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in about 30 to 50 percent of HIV infected individuals. The naturally occurring deletion
mutation of 32-bp in CCR5 is known as CCR5Δ32. Those individuals that carry two
alleles of this are designated as CCR5 -/-. These are the ones that are protected highly
against infection by HIV-1. Those that are heterozygous for this mutant allele are
represented as CCR5 +/- and are not protected against the virus. However this mutation
does delay the infection progression for these individuals. This shows to us the possibility
of a partial resistance if there is presence of a single copy of CCR5Δ32. Only in very rare
cases individual that was homozygous for CCR5Δ32 allele showed HIV infection.
Although the mechanism of infection in such cases has still not been identified, it could
be hypothesized that the virus makes exclusive use of CXCR4 receptor only95, 96.
CCL3, CCL4 and CCL5 are known to suppress infection caused by R5 tropic
strain of the virus. These chemokines sterically block the site where the viral envelope
interacts with the receptor. Similarly SDF-1 a CXCR4 endogenous ligand, leads to
CXCR4 downregualtion thereby blocking the infection caused by X4 tropic strain63, 97.
The anti-CCR5 monoclonal antibody PRO140 (PA14) also inhibits HIV-1 entry along
with inhibiting HIV-1 replication in both peripheral blood mononuclear cells (PBMC)
and primary macrophages. RANTES exhibited a limited antiviral activity in macrophage
cultures98. Using small molecule antagonist to block the binding of gp120 to CCR5 is a
prime approach for anti-HIV therapeutics. Maraviroc was the first and only CCR5
antagonist approved for public use. It acts as an allosteric and non-competitive inhibitor
of the receptor. One limitation to using a CCR5 antagonist for ART therapy is that it will
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be ineffective in people that are infected with X4 strain of the virus. However despite
that, one major advantage of CCR5 antagonist over other therapies is that it targets the
cellular rather that viral protein. Because of this there are less chances of developing viral
resistance99.

2.4.3 CCR5 and Prostate Cancer
As explained before, chronic inflammation is perpetrated to be at the root of
several cancers, including prostate cancer. Progression of various cancers has been
marked by increased expression of members of chemokine network. CCR5 in relation to
cancer was first noticed in breast carcinoma. It was observed that CCL5 along with
corresponding receptor CCR5, induced migration of breast cancer cell lines100. When
measured, RANTES was found to be constitutively expressed by breast cancer cell lines,
T47D and MCF-7, at high and physiologically relevant conditions. Its expression levels
were also found to be high in tissue biopsies of advanced breast carcinoma101. In certain
studies performed, CCR5 antagonist in presence of CCL5 was found to inhibit breast
tumor growth63,
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. Knowing this and the possible connection between chronic

inflammation and prostate cancer, genetic profiling of several genes and proteins of the
inflammatory network was carried out in prostatic tissue in various disease states. Koenig
et al. demonstrated by RT-PCR that, 67% of PCa specimen showed increased RANTES
expression and 89% showed increased CCR5 expression64.
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In yet another set of experiments, expression of RANTES mRNA was monitored
in PCa cell lines and primary cultures of prostate adenocarcinoma. Human breast
carcinoma cell line MCF-7 was used as control. RANTES was also found to stimulate
cell proliferation in DU-145 and LNCaP cells in a colorimetric assay using WST-1 as the
colorimetric reagent102. It was hypothesized that endogenously synthesized CCL5 may
act directly on the PCa cells by binding to CCR5. To prove this, PCa cells were cultured
in vitro to check if they expressed receptors for CCL5. It was found that cell surface
expression of CCR5 was significantly higher than CCR1 and CCR3 in all the cell lines
that were tested. Also large intracellular pools of CCR1, CCR3, and CCR5 were
observed. This was thought to be due to homologous desensitization via the binding of
RANTES and receptor internalization (Table 2)102.
To further explore the realm of RANTES and CCR5 involvement in PCa, studies
were carried out where the cell lines were treated with TAK-779, a non-peptide CCR5
antagonist. TAK-779 was shown to inhibit RANTES induced cell proliferation,
suggesting that CCR5 antagonist could possibly be an effective inhibitor of tumor growth
and progression(Figure 7). Growth of cells exposed to TAK-779 in the absence of
RANTES was not inhibited102.
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PC-3

LNCaP

DU-145

CCR1 surface

0

22.6

16.6

CCR1 total cellular

35.2

52.4

50.2

CCR3 surface

6.1

29.5

8.0

CCR3 total cellular

95.0

88.6

77.8

CCR5 surface

28.8

48.3

38.8

CCR5 total cellular

88.3

89.5

98.6
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TABLE 2: Expression of various CCL5 receptors in prostate cancer cell lines.
The values are represented as percentage of positive cells determined by comparing the
fluorescence emitted on staining with specific antibodies102.
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FIGURE 7: The RANTES stimulation of DU-145 prostate tumor cell
proliferation. Cell proliferation was measured in response to varying concentration of
RANTES (1-100 ng/ml) after 24 hours by the addition of WST-1 proliferation reagent.
The absorbance was measured at 450 nm. Astericks indicate statiscally significant
differences between the control cells and cells exposed to RANTES102.

Detecting the expression of CCL5 and CCR5 in the prostate cell lines, and also
the observation that TAK-779, a known CCR5 antagonist, inhibits RANTES induced cell
proliferation in prostate cancer cell lines, proves to us that CCR5 could be an eligible
target for PCa treatment. Lot of research is being done by industries to come up with
CCR5 antagonist mainly for ART therapy to treat AIDS. However, only one has
managed to clear the clinical trials till date. This makes it necessary to come up with a
novel lead compound that will have the antagonistic properties of the current CCR5
antagonists being tested, without the issues that are associated with it.

2.5 Natural Product as a CCR5 antagonist
Due to the hot interest generated by discovery of CCR5 as an essential HIV entry
coreceptor, a lot of pharmaceutical companies started doing high-throughput screening to
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search for lead compounds that would target CCR5. The very first antagonist identified
was TAK-779 published by Takeda Chemical Industries Ltd. in 1999103. It was obtained
by optimizing compound 1, an initial lead containing quaternary ammonium salt with an
IC50 of 390 nM. TAK-779 however, was unable to be further developed due to its high
toxicity when injected. Following that many modifications were made to come up with a
successful drug but due to different drawbacks none of them made the market.
Companies like Schering-Plough, Merck, Ono Pharmaceuticals, GlaxoSmithKline, came
up with drugs of different structural classes from different leads but none have cleared
clinical trials till date until Maraviroc. Maraviroc or UK-427,857, was capable the first
CCR5 antagonist to be cleared by US Food and Drug administration advisory panel on
24th April 2007. And later, on August 6 it received full FDA approval for use in treatment
of patients104.

FIGURE 8: TAK 779 & lead compound used to generate TAK 779108.

Due to lack of successful antagonists, that have been able to reach the market, it
became important to explore newer realms and try discovering new leads. We know that
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plants and microorganisms provide us with a wealth of unexplored molecules. Although
combinatorial chemistry has become very famous due to its ability to provide new leads,
it sometimes fails to provide the expected answers. In such cases, it is more fruitful to go
back to nature. Natural medicine has been employed to treat maladies and illness right
from the ancient times. It has especially made a huge contribution towards anti-cancer
research in identifying successful drugs for cancer therapy. The importance of natural
product research is emphasized by the fact that National Cancer Institute has begun
screening natural products extracts against cancer cell lines producing more drug
candidates.

High throughput screening of natural products has come up with many

successful approved anti-cancer drugs like taxol, etoposide, teniposide, vincristine,
navelbine, taxotere, topetecan and irinotecan105.

Natural products offer us many

advantages over synthetic libraries. They differ from synthetic molecules in their
complexity. They have more sterogenic centres, more carbon, hydrogen and oxygen, and
less halogen, nitrogen and sulfur. This provides us with a unique and fresher scaffold for
drug development. Not only this, but they also help us discover unique targets through
novel mechanism of actions. Although it is not very often that the natural product
produced directly by a given organism is the best possible drug candidate, it provides us
with a suitable lead that can be optimized to be made into a successful molecule105, 106.
Anibamine

or

6,8-didec-(1Z)-enyl-5,7-dimethyl-2,3-dihydro-1H-indolizinium

alkaloid was isolated first in 2004 as a TFA salt. It was obtained from Aniba panurensis
by activity guided fractionation for its toxicity towards azole-resistant Candida albicans.
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The sample was isolated from fungi in Guyana using methanol extraction. It was later
also identified to possess CCR5 antagonistic activity and competed for binding with
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I-

gp120, the HIV viral envelope protein to human CCR5 with an IC50 of 1µM. Its log Kow
value was calculated to be 9.1 which suggested that it was of a lipophilic nature. Other
than that it also had an undesirable hemolytic activity, hence requiring structural
modifications to transform it into a more favorable drug candidate107.

FIGURE 9: Anibamine

Anibamine was screened against the DTP 60 human tumor cell panel. This panel
included prostate cancer cell lines PC-3 and DU-145, apart from other cell lines115. Its
total synthesis was completed in our lab almost five years ago by Dr. Li by a ten step
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synthesis starting with acetyl acetone and cyanoacetamide, yielding a mixture of
anibamine and its isomers108.

3. Project Objectives and Design

The chemokine receptor CCR5 has been implicated in many diseases such as
AIDS, cancer, Alzheimer’s, atherosclerosis etc. CCR5 and its endogenous ligand CCL5
has especially been found to be over expressed in breast and prostate cancer cells and has
been proven to assist in cancer development and progression. This makes it a favorable
therapeutic target to combat these diseases. Accordingly, chemokine antagonists are
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being studied for their pharmacological applications86. CCR5 has particularly become a
very hot target in anti-HIV therapy development due to its involvement as a co-receptor
for viral entry into the host cell. However, this project mainly deals with development of
CCR5 antagonist to treat prostate cancer.
Identification of three endogenous ligands of CCR5 – RANTES, macrophage
inflammatory protein–1 α, and macrophage inflammatory protein-2 β, lead to research for
developing synthetic compounds to block this receptor. Many pharmaceutical companies
came up with compounds through high throughput screening. However till date only
maraviroc has managed to clear the rigorous US FDA clinical trials (TABLE 3). Due to
adverse effects, poor bioavailabity and long term toxicity of the molecules, not many
CCR5 antagonists have been successful enough to enter market108.

TABLE 3: CCR5 antagonist in clinical trials108
PRODUCT

Maraviroc

MECHANISM OF
ACTION

COMPANY

Non-competitive
inhibitor

Pfizer

STATUS

FDA approved
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Viciviroc

Non-competitive
inhibitor

Schering-Plough

Phase III completed

Aplaviroc

Non-competitive
inhibitor

Glaxosmithkline

Development
discontinued

INCB009471

Non-competitive
inhibitor

Incyte

Phase I/IIa
completed

TBR 652

Non-competitive
inhibitor

Tobira

Phase II completed

Pro 140

Antibody

Progenics

Phase II

HGS004

Antibody

Human Genome
Sciences

Phase I completed

A few years back, screening of natural products extracts obtained from microbial
fermentation, led to the discovery of anibamine. Anibamine is a pyridine quaternary
ammonium alkaloid isolated from Aniba panurensis. Till date it is the only natural
product known that has CCR5 antagonistic ability. It was found to bind CCR5 with an
IC50 of 1µM107. Its anti-metastatic potential was proved by the fact that it interfered in
the PCa cell lines growth in a growth dependent manner. To evaluate its specificity
towards targeting cancer cells, hemolysis of sheep red blood cells was examined at a
concentration of 1µM and below. No toxicity was noticed until the concentration was
increased by 10-fold which supported the potential selectivity of the compound.
Furthermore, immunohistochemical analysis of M12 cells showed that on addition of
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anibamine the morphology of the cells changed. The cells that appear as a disorganized
mass reflecting the metastatic ability of the cell line, turned into a more spheroid
structure. This corroborated with the theory that anibamine has potential to inhibit
prostate tumor metastasis. Preliminary studies also showed that anibamine has the ability
to reduce the subcutaneous growth of M12 cells injected in athymic nude mice109
(FIGURE10).
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FIGURE 10: Effect on anibamine on prostate tumor growth in mice. Six nude mice were
used and were injected with M12 cells. Anibamine was injected once the tumor became
visible at 0.3mg/kg concentration. Tumor size versus number of days after injection was
recorded109.

Anibamine provides us with an unmatched skeleton compared to the other small
CCR5 antagonists that were identified through high throughput screening targeting
mainly anti-HIV therapeutics development. Molecular modeling studies showed us that
there are distinct similarities and differences between binding of anibamine to the
receptor when compared to other known antagonists (FIGURE11 &12)110. All in all the
preclinical studies proves to us that anibamine could not only be a possible candidate for
high affinity CCR5 antagonist, it also has a novel skeleton that might resolve the issues
that the current antagonists are having.
Despite all this, anibamine also had certain shortcomings that did not make it an
ideal drug candidate. Its calculated log Kow was found to be 9.2 which did not conform to
the ‘Lipinski’s Rule of Five’ for drug like compounds. Also compared to other known
CCR5 antagonist it had very simple undecorated aliphatic side chains. Hence, there was
scope for improvement. In spite of these drawbacks, anibamine still serves as an
indispensable lead compound from which different analogues can be designed and
synthesized to use in metastatic cancer therapy. Its unique structure and promising in
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vitro as well as in vivo experimental data, provides us with the much needed platform to
design more ideal drugs109.

Maraviroc
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FIGURE 11: Binding mode of Maraviroc (purple) in homology model of
CCR5110.

Anibamine
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FIGURE 12: Binding mode of anibamine (orange) in homology model of
CCR5110.
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3.1 PROJECT DESIGN
Anibamine was first totally synthesized in our lab in 2007 (FIGURE 3)111. Its
synthetic route was figured out with the help of retrosynthetic analysis. Two synthetic
routes were explored to prepare intermediate 6. From there anibamine (13) was
synthesized in seven more steps.
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FIGURE 13: The complete synthetic route of anibamine111.

To further improve its characteristics and develop newer and better analogs, it
became essential to establish a structure-activity relationship for this compound. This task
was

approached

by

using

‘Deconstruction-Reconstruction-Elaboration’

strategy

(FIGURE 14). By doing this different analogues were designed and synthesized in our
lab. This approach helped us to determine the influence of various substituent groups of
anibamine on its potency, receptor affinity, receptor selectivity, toxicity, functional
activity etc.
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FIGURE 14: Anibamine as lead compound

a) Deconstruction of side chains was done to test its influence on the anti-cancer
activity.
b) Elaboration of the side chains by changing the configuration of the double bond
or completely removing it was done.
c) Deconstruction and elaboration of the ring was done by removing it or changing
its size to test its importance.
Primary structural modifications were focused on fused ring size of the
compound. Different analogues with five, six and seven membered ring were synthesized
and tested. It appeared that seven membered ring was not favorable for binding and most
of the other analogues did not show a marked improvement of the activity profile over
that of the lead compound. Apart from this, isomerization and saturation of the double
bond was also performed to test its affect on the anti-prostate activity. For a single cell
line the different analogues showed more or less similar activity112. This validated the
need for a more comprehensive structural change in the lead compound to establish a
more accurate structure activity relationship spectrum.
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Other than these ongoing modifications to the structure, it was noted that the two
side chains were completely undecorated and simple. Significant modifications done on
these side chains could give revealing results that could go a far way in establishing an
important aspect of the structure-activity relationship and also generate next generation
lead compound. Also, since the molecule was determined to be highly lipophilic,
modifying the plain aliphatic side chains could also help in solving this issue.
Keeping this in mind, an amide bond was introduced as a linkage for the side
chain so as to introduce hydrogen bonding and also to make use of its partial double bond
character. Also the position of the amide bond on the chain was shifted as compared to
the original structure, increasing its distance from the ring. To the amide bond, an
aromatic moiety was attached to simulate the aliphatic carbon length. An amide bond acts
as an isostere for a double bond and hence is a suitable candidate to replace it without
causing too drastic a change in the possible activity. For further optimization, certain
substitutions were introduced at the para position of the phenyl ring, to give the
compound different characteristics and also to obtain the best possible combination
(TABLE 4). These substituents were chosen on the basis of Craig’s plot so as to get all
possible blends with respect to electronic characteristics, lipophilicity, bulkiness and
hydrogen bonding.
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TABLE 4: Different substituents for R.

BULKY GROUPS

ELECTRON WITHDRAWING

ELECTRON DONATING

56

3.2 Project Objectives
The primary objective of this project is to prepare different analogues of
anibamine and help structure an SAR for our lead compound. We also wish to test our
hypothesis that by embellishing the two simple aliphatic side chains we can decrease the
lipophilicity of anibamine to acceptable levels. By doing so we would also establish the
significance of these two side chains in the SAR. Ten analogues were prepared, each with
a different type of substituent to give different electronic properties to the compound. The
synthetic route of anibamine preparation was altered to accommodate these changes.
Following this, biological profiling of the synthesized compounds was carried out.
Three assays were performed – anti-proliferation assay, cytotoxicity assay and calcium
mobilization assay. Anti-proliferation assay was done on PC-3, DU-145, and M12 cell
lines. All of these cell lines express CCR5 receptor on their surface. WST-1 was
colorimetric agent that was used. These anti proliferative studies were performed to test
the ability of the CCR5 antagonist to inhibit the proliferation of prostate tumor cells.
Cytotoxicity assay was performed on NIH-3T3 cell line. It’s performed to measure the
therapeutic index of the drug. Finally the calcium assay was done to identify compounds
that will inhibit the intracellular calcium release stimulated by endogenous ligand
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RANTES. Only the compounds with high affinity for the receptor will be able to inhibit
the binding of RANTES to the receptor. This is a functional assay.
These biological assays will help in validating our hypothesis and also confirm
the structure-activity relationship of the lead compound.

4. Results and Discussion
4.1 Chemical synthesis of Second Generation Anibamine Analogues
The total synthesis of anibamine was completed in our lab in 2007111. In order to
accommodate the changes made in the anibamine structure to generate second generation
anibamine analogues, the synthetic route for total synthesis of anibamine was modified.
The complete route involved synthesis of two key intermediates 6, 14. Synthesis of 6 was
accomplished by using two alternate routes.
4.1.1 Synthesis of key intermediate 6
SCHEME 1: Two routes for synthesis of intermediate 6.

58

SCHEME 2 : Route 1 for synthesis of intermediate 6
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Scheme 1 involved four steps in all. Although it was longer than scheme 1, it
proved to be much easier to carry out. Starting material used in this scheme was acetyl
acetone. It was refluxed with N,N-dimethylformamide dimethyl acetal for about three
hours113. The condensation between the two reagents gave product 1. It was then purified
by recrystallizing from EtOAc giving 85% yield in light yellow crystals. Compound1 was
refluxed with hydroxylamine hydrochloride in MeOH under acidic conditions to give
product 2114. This product was purified by distillation under reduced pressure conditions
furnishing 65% yield. Following that compound 2 was yet again refluxed with aniline to
give a β-enaminonitrile product 3 in 62% yield115. Compound 3 was purified by
recrystallization in EtOH. Refluxing malononitrile with compound 3 under basic
conditions yielded the key intermediate 6. Purification of this compound proved to be a
little difficult. Glacial acetic acid was used to recrystallize pure light yellow crystals,
however care was taken to ensure complete removal of the acid from the crystals which
otherwise proved harmful for the next reaction116. To ensure this, the crystals were
washed thoroughly with cold MeOH. Product yield of this reaction was 89%.

SCHEME 3 : Route 2 for synthesis of intermediate 6
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Route is shorter, comprising only three steps, proved to be more cumbersome
than the other. This was mainly due to the last, key intermediate synthesizing step. The
starting material of this route was also acetylacetone. This was condensed with
cyanoacetamide at room temperature in a basic potassium carbonate solution to give
product 4117. This product required no purification and was obtained at a good yield of
94%. Compound 4 was then brominated at 5th position of the pyridine ring using NBS as
the brominating agent118. It was purified by recrystallization in acetone and water mixture
in 73% yield. The next and last reaction of this scheme was an 80 year old Rosenmondvon Braun reaction. This reaction utilizes cuprous cyanide as the nitrile source and DMF
as the high boiling solvent. The reaction was carried out at a very high temperature of
greater than 150°C. This reaction proceeds by nucleophilc substitution of the bromide
with the nucleophile119.

SCHEME 4 : Mechanism of Rosenmund-von Braun reation.

Over the period of time as the reaction proceeded, its color changed from yellow
to a very dark brown. Also it had a very thick consistency which made it difficult to work
with. The reaction was quenched using acidic FeCl3 solution. The mechanism of this
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reaction involves oxidative addition of the nitrile to the starting material forming a
copperIII complex. This complex is reduced via reductive elimination to yield the
corresponding aryl nitrile and copper halide as the side product. Isolation of the product
from the reaction mixture proved to be a very time consuming and difficult step.
Neutralizing the reaction mixture caused formation of a thick viscous mass which trapped
the product. It was very tricky to remove copper halide from the reaction mixture.
Extraction using EtOAc and dichloromethane was performed that extracted the product
from above and below the reaction mixture. The obtained product 6 was then purified by
crystallization using glacial acetic acid again taking care to completely get rid of the acid.

4.1.2 Synthesis of key intermediate 14

SCHEME 5 : Synthesis of intermediate 14
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The first step of synthesis of 14 was a bromination step. The hydroxyl group at 2nd
position was brominated using tetrabutylammonium bromide as the brominating reagent
to give 7. The reaction was carried out at about 90-100°C for 6 hours120. Although
presence of electron withdrawing group at 3rd position should aid reaction, the reason
why it still took such a long time was due to the presence of hygroscopic phosphorus
pentaoxide. P2O5 was added to provide the phosphate leaving group. However, at the
reaction temperature it melted and formed a black viscous mass at the bottom of the flask
trapping the starting material. This also explained the reason why this reaction did not
give higher yields. Using higher amount of solvent and increasing the equivalents of the
brominating agent increased the yield considerably. Also to ensure maximum stirring
efficiency, mechanical stirrer was used for the reaction. Using mechanical stirrer helped
displacing the trapped starting material from the melted P2O5 mass. Purification was done
via column chromatography on Al2O3 column.
From here the introduced bromide group at 2 position was coupled with PMB
protected propargyl alcohol through Sonogashira coupling. Before the coupling reaction
the 16 was prepared (SCHEME 6).

SCHEME 6: Synthesis of 16
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In this two step reaction, a solution of sodium hydride was added to 4-methoxy
benzyl alcohol under nitrogen protection. This caused deprotonation of the starting
material at which point tricholoroacetonitrile was added at 0°C to form 4-methoxybenzyl
trichloroacetimidate. On concentrating the mixture, a yellow crude oil was obtained
which was then dissolved in CH2Cl2. To this solution propargyl alcohol was added
dropwise and cooled to 0°C. A catalytic amount of 10-camphorsulfonic acid was added
till the pH of the solution was around 3 - 4. The reaction was allowed to come to room
temperature overnight121. This protecting group was purified through column
chromatography giving colorless oil in 83% yield.
For Sonogashira reaction, compound 7 was dissolved in diethyl ether and to this
CuI, Pd(PPh3)2Cl2, and TEA was added. Once everything dissolved, the PMB protected
propargyl alcohol solution in ether was added to the reaction slowly under N2 protection.
The reaction was allowed to go on for 24 hours over the course of which brown
precipitate formed in the ether layer122. The precipitate was extracted using EtOAc and
purified using column chromatography. Care was taken during purification as it was
difficult to get rid of the catalyst used during the reaction and further crystallization was
required in MeOH to finally get the pure product in a 66% yield. Another method for
removing the residual catalyst of the reaction was to pass the reaction mixture first
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through an Al2O3 column and then performing the usual purification protocol. It was
observed that if the product was not pure, it poisoned the catalyst used in the next
reaction giving low yields.
Following the coupling reaction, the triple bond was reduced by hydrogenation
using Pd/C catalyst. The starting material 8 was dissolved in methanol and catalytic
amount of catalyst added. The reaction was carried out on Barr hydrogenator at H2
pressure of 56-58 psi. This was a clean reaction requiring no further purification and
furnished high yields of 96%.
After reducing the triple bond, the synthetic route was deviated from original
anibamine synthetic route in order to reduce the cyano groups to amine instead of
aldehyde. This reaction initially posed lots of problems. It was difficult to achieve the
reducing conditions strong enough to reduce the two cyano groups yet at the same time
not too strong so as to cleave the PMB protected group. Several, chemical methods were
tried such as using NaHPO2 as the reducing agent. But at the end of the reaction when the
TLC was examined, it showed degradation of the PMB protecting group. Varying the
reaction conditions proved to have no effect on the outcome. Following that
hydrogenation was attempted using 10% w/w Pd/C catalyst. However, even after
prolonged reaction time, no change was noticed in the starting material. Finally after
researching some more literature a different approach was tried. The catalyst was
changed to 50% w/w Raney Nickel and glacial acetic acid was used as the solvent. On
doing so, the reaction was completed in 48 hours and an examination of the TLC showed

65

formation of primary amine. This was further confirmed by doing ninhydrin test for
primary amines. The product was concentrated thoroughly to completely get rid of the
acid and then purified by column chromatography to give intermediate 14.

4.1.3 Synthesis of final compounds.
The last stage in the final compound synthesis was introducing different side
chains at 3 and 5 position of the pyridine ring. The two amino methyl groups were
coupled with acid to form amide bond. Each acid had a different sustitution at the para
position. The different acids used are listed below.

FIGURE15: List of acids used in coupling reaction.
SCHEME 7: Amide coupling reaction
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This acid-base coupling reaction was carried out by using EDC or 1-ethyl-3-(3dimethylaminopropyl) carbodiimide hydrochloride as the coupling reagent. The
carbodiimide acts as a carboxyl activating agent for the coupling of primary amines to
yield amide bonds. It reacts with acid to form an O-acylisourea. This then reacts with
amine to give the corresponding amide. However, there are also some side reactions that
take place. The O-acylisourea can rearrange to form a stable N-acylurea which would
stop the reaction. To avoid this dichloromethane was used as the solvent since it had low
dielectric constant.

SCHEME 8: Side reactions of the coupling reaction.
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For this reaction it is very important to maintain anhydrous conditions. Molecular
sieves were used and also the reaction was carried out under N2 atmosphere. Also the
reagents were added in the right sequence to avoid side reactions. First 2.1 equivalents of
acid were stirred with EDC, HOBT, TEA and solvent for 15 mins in ice bath. To this a
solution of amine in DCM was added slowly. The reaction was allowed to carry out at
room temperature overnight. To ensure that both the groups were allowed to form the
amide bond with acid, 1 equivalent acid along with EDC, HOBT and TEA were added
next day. The reaction was allowed to proceed for another 24 hours or till all of the
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starting material was used up. The product was extracted using DCM from the mixture
and purified using column chromatography. The yield of this reaction varied with
different types of acids.
After the side chains were coupled, the PMB protecting group was cleaved to
expose the alcohol which was cyclized to give the final product.

SCHEME 9: Deprotection reaction

1N hydrochloric acid in ethanol was used to carry out the deprotection reaction.
The reaction was allowed to reflux for 5-6 hours depending on the side chain. The acid
was neutralized using ammonium hydroxide and the entire mixture was filtered. This is
done instead of direct extraction due to the high water solubility of the product. After
concentrating and removing all traces of water, the crude product was purified on silica
gel column to give compounds 18 a-j.
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The last step of the synthesis was the cyclization step. Methane sulfonyl chloride
in presence of TEA was used as the cyclizing agent giving the final indolizinium ion salt.
The reaction was carried out at 0°C in anhydrous dichloromethane and allowed to come
to room temperature over 1 hour.
SCHEME 10: Cyclization reaction
O
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Due to lack of difference in polarity between the final compound in salt form
and TEA.HCL salt formed during the reaction, it became difficult to extract the former.
Various methods were tried to separate the two salts. Even after passing through silica gel
column traces of triethylamine salt still remained. So to extract the salt completely,
consecutive washings with 1N HCl were performed. This effectively removed the TEA
salt and the final compound was purified by column chromatography in CH2Cl2: MeOH
solvent system. The purity of the final compound was also tested by performing HPLC.
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Finally ten new second generation analogues of anibamine (19 a-j) with variable
side chains were prepared by modifying the original route. All the final compounds were
in their chloride salt form. The compounds were all characterized using H1 NMR, C13
NMR, IR, mass spectrometry and HPLC. Following their synthesis, they were screened
for biological activity.
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4.2 Biological screening of Second Generation Anibamine Analogues
The ten final compounds were screened for three biological assays. These were
anti-proliferation assay and cytotoxicity assay, calcium mobilization assay.

4.2.1 Anti-proliferation assay.
Anti-proliferation assay is performed to observe the proliferation inhibition
effects of the synthesized ligands on PCa cells. The cell lines used for this assay included
PC-3, DU-145 and M12. The assay was miniaturized by culturing the cells in a 96-well
plate in order to test higher number of drugs together. The media used for PC-3 and DU145 cells was RPMI, 1% L-glutamine, 0.1% ITS (insulin, 5 μg/mL; transferring, 5
μg/mL; and selenium, 5 μg/mL) and 0.1% gentamicin. The media for M12 was slightly
different from that of PC-3 and DU-145. It contained 5% fetal bovine serum instead of
the 10% used for PC-3 and DU-145. About thousand cells were plated per well in 100 μL
of media. On the second day, various concentrations of the drugs were added to make up
the volume to 150 μL. The cells were incubated for 72 hours following which the media
was dumped out and anti-proliferative reagent WST-1 was added. The cells were
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incubated for three more hours at the end of which absorbance of each well was
measured at 450 nm.
The anti-proliferative reagent used for this assay is a tetrazolium salt that acts as a
colorimetric agent. The advantage of using this salt was that it required no prior
solubilization step before enzymatic cleavage as needed by previously used salts. WST-1
is cleaved by enzyme mitochondrial reductase into a water soluble formazan dye that is
dark red in color. The tetrazole ring of the dye opens up when the enzyme system
introduces hydrogen into the structure. The energy for the reaction is obtained by
reducing NADH into NAD+ by electron chain transport system. Only the viable cells
have the ability to cleave the salt and form formazan. So higher the number of viable
cells, greater the amount of formazan formed. The color change form can be measured
using an ELISA instrument. The incubation time with WST-1 has been optimized to three
hours and has produced the best proliferative results.
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FIGURE 16: Metabolically driven WST-1 cleavage to form water soluble
formazan dye. RS – mitochondrial cleavage, EC – electron coupling reagent127.

PC3

M12

DU145

IC50

SEM

IC50

SEM

IC50

SEM

19a

192.1

17.6

101.4

11.4

72.7

16.2

19b

184.8

4.9

243.5

2.5

149.9

13.1

19c

169.3

13.6

161.9

8.3

107.9

9.5

19d

49.1

1.2

47.1

8.4

43.4

1.1

19e

98.6

0.1

107.4

1.6

100.8

4.6

19f

120.2

6.6

167.9

43.0

139.3

13.8

19g

127.0

13.1

153.9

5.3

123.8

3.7
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19h

92.0

25.0

147.3

5.0

107.3

3.1

19i

134.7

23.1

178.6

18.0

120.4

26.2

19j

160.9

26.5

>300

NA

181.8

13.1

TABLE 5: Anti-proliferation data of the ten final compounds in three different
PCa cell lines.

Discussion:
According to the data obtained, compound 19d shows the best anti-proliferative
activity in all the cell lines, persistently. It displayed the lowest IC50 of 43.4µM for DU145 cell line while the highest value of 49.1 µM for PC-3 cell line. Majority of the
compounds displayed better activity for DU-145 cell line as compared to the other two
cell lines. Apart from 19d that had an IC50 of 43.4 µM, 19a was another compound that
showed a lower IC50 of 72.7 µM compared to other compounds. It was also noticed that
some of the compounds like 19g, 19h and 19e showed better activity profile in PC-3
cells.
This difference in the values among the cell lines probably was due to the fact that
all the cell lines do not exhibit same level of CCR5 receptor expression. PC-3 shows the
lowest CCR5 expression as compared to M12 and DU145. The varied level of receptor
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expression in the cell lines may affect the function of the drugs. Apart from that, the
downstream signaling pathways of the receptor may counterbalance differently the
antagonism of CCR5 among different cancer cell lines. This also probably explains the
reason why some of the other compounds like 19h and 19j did not show consistent
results among the three different cell lines.
By examining the trend in the IC50 values it can be deduced that maintaining the
hydrophobicity in the side chain is essential for the activity. For DU-145 cell line, bulkier
groups showed better inhibition of the proliferation. 19d that displayed the best activity
had a phenyl subsitiution, and 19a having an IC50 of 72.7 had a naphthalene substitution
supporting our conclusion.

FIGURE 17: Structure of 19d and lead compound anibamine.

More polar substitutions hampered the activity which is proved by 19h, 19f and
19i with IC50 of 181.8 µM, 139.3 µM and 120.4 µM respectively. Also 19d had the
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longest side chain length out of all the analogues proving to us that maybe keeping the
chain length conserved is also imperative for the activity.

4.2.2 Cytotoxicity assay.
Cytotoxicity is the harmful effect induced by a compound in a cell culture system
in vitro. It acts as a measure of the potency of the drug and also its effect on normal cells.
It can be performed by both qualitative and quantitative methods. For this project we
used a method that measures the metabolic integrity of the cells. The cell line used was
NIH3T3 cell line. It’s a primary mouse fibroblast cell line. Like anti-proliferation assay
the agent used to detect the cell viability was WST-1. If the membrane of the cell is not
ruptured by the drug and it is still viable, the mitochondrial reductase enzyme will break
down WST-1 to form a water soluble formazan dye that imparts red color. Color intensity
is measured in terms of absorbance and TC50 is calculated.
IC50±SEM (μM)
3T3(WST-1)
19a

165.6±4.7

19b

229.0±2.3

19c

254.7±10.6

19d

227.8±13.6
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19e

171.2±18.4

19f

269.5±3.9

19g

>300uM

19h

181.8±5.5

19i

263.4±27.6

19j

226.4±13.2

TABLE 6: Cytotoxicity results of the final compounds.

Discussion:
Measuring TC50 gives us a measure of the effect of the drug on normal cells. It’s
the ability of the drugs to induce death in 50% of the cells as compared to control. If the
drug is cytotoxic, it causes necrosis and the cell membrane ruptures. The cell ruptures as
a result of cell lysis. Looking at the cytotoxicity results it is apparent that except for 19a
most of the compounds have a very low cytotoxic profile and that they require higher
concentrations to induce toxicity in 3T3 as compared to prostate cancer cell lines.
Compound 19d which showed the highest activity shows a high LD50 of 227.8 µM. 19a
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appeared to be cytotoxic for cells and hence not suitable. Also compared to the lead
compound anibamine that had a TC50 of 23.47 µM, all the compounds displayed low
cytotoxicity in the cells. Compound 19g was the least toxic with TC50 of >300 µM.

4.2.1 Calcium mobilization assay.
This assay is performed for in-cell measurement of agonist-stimulated and
antagonist-inhibited calcium signaling through CCR5 receptor. It is performed on
MOLT-4 cell line expressing surface CCR5 receptors. This cell line was obtained from
acute lymphoblastic leukemia cells of a human. Fluo-4 is used as the indicator dye. It has
an affinity for Ca2+ ions, exhibiting a KD of 345 nM (ref). When at rest it displays low
emission intensity, however, when bound to calcium it emits very high intensity
fluorescence. When the receptor binds to agonist RANTES, the level of intracellular
calcium ion increases which can be detected by the Flou-4 dye. However, in presence of
an antagonist the receptor binding with agonist is blocked and the calcium ion release
thereby obstructed. This is revealed by decrease in emission intensity of the dye. The
assay data for the first five compounds is displayed below.

IC50 (µM)

SEM
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19a

12.7

0.9

19b

18.7

1.2

19c

23.9

0.9

19d

17.3

1.8

19e

38.5

13.1

TABLE 7: Inhibitory effects on CCL5 induced Ca2+mobilization in MOLT4/CCR5 cells.

Discussion:
From the assay results of the first five compounds that were tested, it is apparent
that all of them show antagonistic ability towards CCR5 receptor. Lowest IC 50 was
displayed by 18a. This can be interpreted as; 19a has the ability to inhibit binding of 50%
of the RANTES to the receptor at a concentration of 12.7 µM. 19b that showed greatest
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anti-proliferation activity, displayed an IC50 of 17.3 µM. These results are consistent
with the anti-proliferation assay obtained. Both 19a and 19d that had showed the lowest
IC50 for the anti-proliferation assay also displayed the lowest IC50 in the calcium
mobilization assay. This also further supports our theory that having a bulky and
hydrophobic group in the side chain is important for the activity of the compound.
Compound 19d while showed the best anti proliferative activity, yet did not show
the best antagonistic activity. This can be explained by the fact that antagonism of the
drug may not correlate to its activity. This can be explained by the phenomenon of
functional selectivity. A GPCR has the ability to attain several multiple active isoforms.
These sites can be stabilized by ligands so that only a certain part of the complete
signaling pathways are selectively activated. The ligand can bind to one of the isoforms
of the receptor and still cause differential changes depending on the cellular localization
of the receptor-G protein complex. One of the mechanisms to explain this is probably the
atypical conformational changes induced as compared to endogenous ligand.

5. EXPERIMENTAL

5.1 Chemical Synthesis
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Melting points were determined on a Fisher-Scientific melting point apparatus. 1H-NMR
and

13

C-NMR spectra were obtained on a Brucker 400 MHz spectrometer and

tetramethylsilane was used as an internal standard. Infrared spectra were obtained on a
Nicolet 5ZDX FT-IR spectrometer. Column chromatography was performed on silica gel
(grade 60 mesh; Bodman Industries, Aston, PA). Routine thin-layer chromatography
(TLC) was performed on silica gel GHIF plates (250 µm, 2.5 x 10 cm; Analtech Inc.,
Newark, DE).

Scheme 1:
3-((Dimethylamino)methylene)pentate-2,4-dione

A solution of N,N-dimethylformamide dimethyl acetal (35.7 g, 0.3 mol) and
acetylacetone (15 g, 0.15 mol) was refluxed for 3 hours. The mixture was then
concentrated to remove excess acetal to give a dark red oil. The crude product was
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recrystallized

in

ethyl

acetate

to

give

light

yellow

crystals

of

3-

((dimethylamino)methylene)pentate-2,4-dione (19.75 g, 85% yield). M.p. 55-57°C
1

HNMR (400 MHz, CDCl3) 7.45 (s, 1H), 3.1 (s, 6 H), 2.34 (s, 6H).

1-(5-Methylisoxazol-4-yl)ethanone

3-((dimethylamino)methylene)pentate-2,4-dione (19g, 0.122 mol) was added into a
solution of hydroxylamine hydrochloride (8.47g, 0.122 mol) in 60 mL methanol. This
solution was refluxed for 2 hours. The mixture was concentrated to remove methanol and
then partitioned between 100 mL water and 200 mL dichloromethane. The
dichloromethane layer was dried over Na2SO4, filtered and concentrated to give a crude
red residue. The residue was purified by reduced pressure distillation (95°C, 10 torr) to
give a colorless oil of 1-(5-methylisoxazol-4-yl)ethanone (9.95 g, 65% yield). 1HNMR
(400 MHz, CDCl3)

8.49 (s, 1H), 2.74 (s, 3 H), 2.45 (s, 3H).

(E)-2-Methyl-4-oxo-3-(phenylamino)pent-2-enenitrile
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A mixture of aniline (20.38 g, 0.218 mol) and 1-(5-methylisoxazol-4-yl)ethanone (9.1 g,
72.8 mmol) was refluxed for 30 minutes. After cooling, the mixture was poured into ice
cold 100 ml 2N HCl and stirred while a precipitate formed. The precipitate was
recrystallized in ethanol to give (E)-2-methyl-4-oxo-3-(phenylamino)pent-2-enenitrile
(9.28 g, 62% yield) as clear plate crystals. M.p.: 132-133°C

1

HNMR (400 MHz, CDCl3)

7.46 (m, 3H), 7.14 (m, 2H), 2.41 (s, 3H), 2.27 (s, 3H).

Scheme 2:
2-hydroxy-4,6-dimethylnicotinonitrile

To a solution of K2CO3 in water (20 ml), cyanoacetamide (0.84 g, 10 mmol) and
acetylacetone (1.00 g, 10 mmol) was added. The reaction mixture was stirred overnight at
room temperature. The precipitate was filtered and washed with hexane to give 2-
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hydroxy-4,6-dimethylnicotinonitrile (1.385 g, 94% yield) as a white powder. M.p.: 188189°C 1HNMR (400 MHz, CDCl3) 12.38 (br, 1H), 6.12 (s, 1H), 2.3 (s, 3H), 2.23 (s,
3H).

5-bromo-2-hydroxy-4,6-dimethylnicotinonitrile

A solution of 2-Hydroxy-4,6-dimethylnicotinonitrile (1.2 g, 8 mmol ) in trifluoroacetic
acid (1.28 mL) was cooled to 0˚C. To this mixture concentrated H2SO4 (1.7 mL) was
added followed by slow addition of NBS (2.88 g, 16 mmol). The reaction was kept at 0˚C
and stirred for 1.5 hours then poured into crushed ice. The resulting precipitate was
filtered and recrystallized in a 4:1 mixture of acetone and water yielding 5-bromo-2hydroxy-4,6-dimethylnicotinonitrile (1.34 g, 73% yield) as clear white crystals. M.p.:
256-257˚C

1

HNMR (400 MHz, CDCl3)

12.83 (br, 1H), 2.43 (s, 3H), 2.37 (s, 3H).

2-hydroxy-4,6-dimethylpyridine-3,5-dicarbonitrile
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Method 1: (E)-2-methyl-4-oxo-3-(phenylamino)pent-2-enenitrile (9.1 g, 44.3 mmol)
was added to a solution of malononitrile (2.92 g, 44.3 mmol), and KOH (2.48 g, 44.3
mmol) in 150 mL methanol. The mixture was refluxed for 5 hours. After cooled down, it
was concentrated to remove methanol. The dark brown residue obtained was
recrystallized in glacial acetic acid to give white crystals of 2-hydroxy-4,6dimethylpyridine-3,5-dicarbonitrile (6.82 g, 89% yield).

Method 2 : Cuprous cyanide (284.13 mg, 3.17 mmol) was dissolved in DMF (5 mL). To
this, 5-bromo-2-hydroxy-4,6-dimethylnicotinonitrile (600 mg, 2.6mmol) was added. The
reaction was heated and refluxed under N2 protection for 48 hours. On cooling, the
reaction mixture was poured into an FeCl3 solution (4 g FeCl3, 4 mL H2O, 1 ml HCl)
and stirred at 60°C for 15 minutes. Then the mixture was poured over crushed ice and
dilued with 50 ml water. The water solution was neutralized with 1M NaOH and then
filtered. The aqueous solution so obtained was extracted with ethyl acetate (80 x 3 ml)
and dichloromethane ( 50 x 2 ml ). The combined organic layers were washed with brine,
dried over Na2SO4, filtered and concentrated to give 720 mg crude product. The crude
products

were

recrystallized

in

glacial

acetic

acid

to

give

2-hydroxy-4,6-

dimethylpyridine-3,5-dicarbonitrile ( 278mg, 61% yield) as a white powder.
1

HNMR (400 MHz, DMSO) 3.32 (br, 1H), 2.5 (s, 3H), 2.22 (s, 3H).
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After convergence of the two schemes:
2-Bromo-4,6-dimethylpyridine-3,5-dicarbonitrile

A solution of 2-hydroxy-4,6-dimethylpyridine-3,5-dicarbonitrile (5 g, 28.7 mmol),
tetrabutyl ammonium bromide (13.97 g, 43.3 mmol) and phosphorous pentaoxide (12.3 g,
86.7 mmol) was heated in toluene (130 mL) at 100°C under N2 protection for 5 hours.
After cooled down, the mixture was partitioned with brine(50ml) and EtOAc(100ml).
The aqueous layer was then extracted with EtOAc ( 80 x 3 ml ). The combined organic
layers were dried over Na2SO4, filtered and concentrated to give 6.1 g crude brown solid.
The crude product was purified by column chromatography on neutral aluminum oxide
with a Hexane:EtOAc solvent system (6:1 v/v) as eluent to give 2-bromo-4,6dimethylpyridine-3,5-dicarbonitrile (4.26 mg, 67% yield) as a white powder. M.p.: 127129°C

1

HNMR (400 MHz, CDCl3)

2.83 (s, 3H), 2.78 (s, 3H).

1-Methoxy-4-((prop-2-ynyloxy)methyl)benzene (10)
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A solution of 4-methoxybenzylalcohol (3.32g, 24 mmol) in anhydrous Et2O (24 mL) was
added to a suspension of NaH (58 mg, 2.4 mmol) at room temperature and stirred under
N2 protection. After stirring for 30 minutes, the mixture was cooled to 0°C and
trichloroacetonitrile (3.46 g, 24 mmol) was added. The reaction mixture was allowed to
warm up slowly to room temperature over 4 hours. The solution was concentrated to
remove ether and the residue so obtained was dissolved in anhydrous hexane (28 mL) and
anhydrous methanol (0.12 mL) and filtered through celite. It was then concentrated again
to give yellow oil (6.7 g). The crude intermediate was dissolved in 40 ml
dichloromethane. Propargyl alcohol (896 mg, 16 mmol) was added to the reaction. The
solution was cooled to 0°C and 10-camphorsulfonic acid was added until the pH turned
to 3-4. The reaction was stirred overnight under N2 protection while a white precipitate
formed. The solution was filtered through celite, washed with saturated sodium
bicarbonate solution, dried over Na2SO4, filtered and concentrated to give 3.4 g crude
product. The crude product was purified on silica gel with Hexane:EtOAc (20:1 v/v) to
give 1-methoxy-4-((prop-2-ynyloxy)methyl)benzene (2.4 g, 83% yield)as a colorless oil.
1

HNMR (400 MHz, CDCl3) 7.29 (m, 2H), 6.89 (m, 2H), 4.53 (s, 2H), 4.13 (d, J=2.4 Hz,

2H), 379 (s, 3H), 2.45 (t, J=2.4 Hz, 1H).
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2-(3-((4-Methoxybenzyloxy)prop-1-ynyl)-4,6-dimethylpyridine-3,5-dicarbonitrile
(11a)

To a solution of 2-bromo-4,6-dimethylpyridine-3,5-dicarbonitrile (620 mg, 2.6 mmol) in
anhydrous diethyl ether (60 mL), CuI (24 mg, 0.26 mmol), PdCl2(PPh3)2 (91 mg, 0.13
mmol), and triethylamine (18 mL) was added. After stirring for 15 minutes, 1-methoxy4-((prop-2-ynyloxy)methyl)benzene (554 mg, 3.15 mmol) in diethyl ether (2 mL) was
added slowly drop wise under N2 protection. The reaction was allowed to stir under N2
protection overnight while a precipitate formed. Then water (25 mL) was added. The
organic layer was separated and the water layer was extracted with EtOAc (50 x 2 ml).
The combined organic layers were washed with brine, dried over Na2SO4 and
concentrated. Purification by chromatography on silica gel with a Hexane/EtOAc (5:1)
solvent

system

as

eluent

gave

2-(3-((4-Methoxybenzyloxy)prop-1-ynyl)-4,6-

dimethylpyridine-3,5-dicarbonitrile (565 mg, 66% yield) as white crystals.

1

HNMR

(400 MHz, CDCl3): 7.34 (d, 2H), 6.90 (d, 2H), 4.68 (s, 2H), 4.47 (s, 2H), 3.8 (s, 3H),
2.82 (s, 3H), 2.76 (s, 3H).
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2-(3-((4-Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-dicarbonitrile (12a):

A

mixture

of

2-(3-((4-methoxybenzyloxy)prop-1-ynyl)-4,6-dimethylpyridine-3,5-

dicarbonitrile (500 mg, 1.4mmol) and Pd/C (47 mg, 10% by weight) in MeOH (40 mL)
was hydrogenated under 57 psi H2 for 12 hours. The mixture was filtered through celite
to

remove

Pd/C

and

concentrated

to

remove

MeOH

to

give

2-(3-((4-

methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-dicarbonitrile (485 mg, 95% yield)
as a white solid without further purification. 1HNMR (400 MHz, CDCl3)

7.16 (d, 2H),

6.88 (d, 2H), 4.32 (s, 2H), 3.74 (s, 3H), 3.48 (t, J=6.0 Hz, 2H), 3.05 (m, 2H), 2.68 (s,
3H), 2.58 (s, 3H), 2.03 (m, 2H).

(2-(3-(4-Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-diyl)dimethanamine

Hydrogenation was conducted on a mixture of 2-(3-((4-methoxybenzyloxy)propyl)-4,6dimethylpyridine-3,5-dicarbonitrile (350 mg, 1.04 mmol) and wet Raney Nickel slurry
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( 700 mg ) in glacial acetic acid (15 mL) under 58 psi H2 for 24 hours. The mixture was
filtered through celite to remove the catalyst and concentrated to remove AcOH. The
crude product was purified by flash column chromatography on silica gel with
Dichloromethane/Methanol (15:1) to give 2-(3-((4-methoxybenzyloxy)propyl)-4,6dimethylpyridine-3,5-dicarbonitrile (210 mg, 57% yield) as a brown semi-solid.
1

HNMR (400 MHz, CDCl3) 7.16 (m, 2H), 6.88 (m, 2H), 4.32 (s, 2H), 3.74 (s, 3H), 3.48

(t, J=6.0 Hz, 2H), 3.05 (m, 2H), 2.68 (s, 3H), 2.58 (s, 3H), 2.11 (m, 2H).

13

C NMR

(100MHz, MeOD) 159.12, 157.33, 154.37, 144.32, 132.32-129.21, 113.75, 72.47, 69.56,
55.29, 40.1, 39.56, 31.7, 30.33, 22.42, 14.53.

6.1.2 Synthesis of final products :
N,N-(2-(3-(4-methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene)di-2-napthamide

On an ice water bath a solution of napthoic acid (0.311 g , 1.8 mmol) in DMF ( 3ml ), 1(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ( 0.485 g, 2.5 mmol ),
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hydroxybenzotriaoxazole ( 0.342 g, 2.5 mmol ), molecular sieve and TEA ( 0.549g , 5.4
mmol

)

with

N2

protection.

After

20

minutes

a

solution

of

(2-(3-(4-

Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-diyl)dimethanamine ( 0.2 g, 0.6
mmol ) in DMF was added drop wise. After stirring at room temperature overnight the
resulting mixture was filtered through celite. The filtrate was concentrated in vacuum.
The residue was dissolved in 50 ml DCM and washed with brine, dried and concentrated
to give 0.240 g crude. Purification by chromatography on silica gel with a DCM/MeOH
(15:1) as eluent gave 0.140 g product as a white solid in % yield. 1HNMR (400 MHz,
CDCl3) 8.2 (s, 2H), 8.07 (s, 1H), 7.77 (d, , J=8Hz, 2H), 7.68 (d, J=8Hz, 2H), 6.8 (d, 2H),
4.64 (d, d, J=4.68Hz, J=10.04Hz 4H), 4.26 (t, 2H), 3.73 (s, 3H), 3.51 (t, 2H), 3.1 (t, 2H),
2.59 (s, 3H), 2.54 (s, 3H), 2.0 (m, 2H).

N,N-(2-(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene)di-2naphthamide
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The

solution

of

N,N-(2-(3-(4-methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-

diyl)bis(methylene)di-2-napthamide (120 mg, 0.2 mmol) in 6 ml EtOH and 3 ml 1N HCl
was refluxed for 3 hours. After cooled down, the mixture was concentrated to remove
EtOH. The combined organic layers were washed with brine, dried over anhydrous
Na2SO4, filtered and concentrated to give 150 mg crude. Purification on silica gel column
with a DCM / MeOH (10:1) solvent system as eluent to give 80 mg white solid in 82%
yield. 1HNMR (400 MHz, CDCl3) 8.38 (d, 2H), 7.8 (m, 8H), 7.54 (m, 4H), 4.76 (m, 4H),
3.67 (t, 2H), 3.1 (t, 2H), 2.69 (s, 3H), 2.57 (s, 3H), 2.04 (m, 2H).

6,8-(bis(methylene)di-napthylcarboxamide)5,7-dimethyl-2,3-dihydro-1Hindolizinium

Methanesulfonyle chloride (46 mg, 0.4 mmol) was added into the solution of N,N-(2-(3hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene)di-2-naphthamide (75 mg,
0.14 mmol) in 5 ml CH2Cl2 and triethylamine (60 mg, 0.6mmol) at 0°C. The resulting
mixture was allowed to warm to room temperature over 1 hour. The mixture was diluted
with 20 ml CH2Cl2. The CH2Cl2 layer was washed with 1N HCl twice followed by brine ,
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dried over Na2SO4, filtered and concentrated. Purification with chromatography on silica
gel with a CH2Cl2/MeOH (10:1) solvent system as the eluent to give 40 mg pure white
solid in 51% yield.

1

HNMR (400 MHz, MeOD) 8.34 (d, 2H), 7.88 (m, 8H), 7.52 (m,

4H), 4.82 (m, 4H), 4.75 (s, 2H), 3.85 (t, 2H), 2.9 (s, 3H), 2.87 (s, 3H), 2.54 (m, 2H). 13C
NMR (400MHz, MeOD) 170.36 (2 carbons), 158.7, 158.15, 152.32-124.78, 59.19, 39.95,
39.14, 33.107, 21.42, 17.92, 17.62. MS m/z: 514.25

N,N-(2-(3-(4-methoxybezyloxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene)bis(4-methylbenzamide)

On an ice water bath, a solution of benzoic acid (0.291 g , 1.8 mmol) in DMF ( 3ml ), 1(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ( 0.485 g, 2.5 mmol ),
hydroxybenzotriaoxazole ( 0.342 g, 2.5 mmol ), molecular sieve and TEA ( 0.549g , 5.4
mmol

)

with

N2

protection.

After

20

minutes

a

solution

of

(2-(3-(4-

Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-diyl)dimethanamine ( 0.22 g, 0.6
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mmol ) in DMF was added drop wise. After stirring at room temperature overnight the
resulting mixture was filtered through celite. The filtrate was concentrated in vacuum.
The residue was dissolved in 50 ml DCM and washed with brine, dried and concentrated
to give 0.240 g crude. Purification by chromatography on silica gel with a DCM/MeOH
(15:1) as eluent gave 0.15 g product as a white solid in 40% yield. 1HNMR (400 MHz,
CDCl3) 8.2 (s, 1H), 7.77 (d, J= 7.76 Hz, 2H), 7.62 (d, 2H), 7.59 (d, J= 1.96 Hz, 2H), 7.53
(d, 2H), 7.07 (m, 4H) 7.00 (d, 2H), 6.70 (d, 2H), 4.66 (d,d, J= 1.84 Hz, J= 8.40 Hz, 4H),
4.22 (t, 2H), 3.73 (s, 3H), 3.51 (t, 2H), 3.1 (t, 2H), 2.59 (s, 3H), 2.54 (s, 3H), 2.35 (s, 3H),
2.0 (m, 2H).

N,N-(2-(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene)bis(4methylbenzamide)

The

solution

of

N,N-(2-(3-(4-methoxybezyloxy)propyl)-4,6-dimethylpyridine-3,5-

diyl)bis(methylene)bis(4-methylbenzamide) (120 mg, 0.2 mmol) in 6 ml EtOH and 3 ml
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1N HCl was refluxed for 3 hours. After cooled down, the mixture was concentrated to
remove EtOH. The combined organic layers were washed with brine, dried over
anhydrous Na2SO4, filtered and concentrated to give 1650 mg crude. Purification on
silica gel column with a DCM / MeOH (10:1) solvent system as eluent to give 88 mg
white solid in 64% yield. 1HNMR (400 MHz, CDCl3) 7.83 (m, 4H), 7.24 (m, 5H), 4.76
(m, 4H), 3.67 (t, 2H), 3.1 (t, 2H), 2.69 (s, 3H), 2.57 (s, 3H), 2.35 (s, 3H), 2.04 (m, 2H).

5,7-dimethyl-6,8-bis((4-methylbenzamido)methyl)-2,3-dihydro-1H-indolizin-4-ium
chloride

Methanesulfonyle chloride (46 mg, 0.4 mmol) was added into the solution of N,N-(2-(3hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene)di-2-naphthamide (75 mg,
0.14 mmol) in 5 ml CH2Cl2 and triethylamine (60 mg, 0.6mmol) at 0°C. The resulting
mixture was allowed to warm to room temperature over 1 hour. The mixture was diluted
with 20 ml CH2Cl2. The CH2Cl2 layer was washed with 1N HCl twice followed by brine ,
dried over Na2SO4, filtered and concentrated. Purification with chromatography on silica
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gel with a CH2Cl2/MeOH (10:1) solvent system as the eluent to give 40 mg pure white
solid in 51% yield. 1HNMR (400 MHz, MeOD) 8.82 (s, 1H), 8.69 (s, 1H), 7.91 (d, J=
7.92 Hz, 4H), 7.10 (t, 4H), 4.82 (d,d, J= 2.68 Hz, J= 2.96 Hz 4H), 3.71 (m, 2H), 2.79 (s,
3H), 2.69 (s, 3H), 2.48 (m, 2H). 13C NMR (400MHz, MeOD) 167.36 (2 carbons), 158.7,
156.15, 150.34, 152.32-124.78, 57.72, 39.02, 38.33, 32.16, 21.42, 17.92, 17.62. MS m/z:
442.

N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(4-ethylbenzamide)

On an ice water bath, a solution of p-ethylbenzoic acid (0.291 g , 1.93 mmol) in DMF (
3ml ), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ( 0.520 g, 2.7
mmol ), hydroxybenzotriaoxazole ( 0.366 g, 2.7 mmol ), molecular sieve and TEA (
0.589g , 5.8 mmol ) with N2 protection. After 20 minutes a solution of (2-(3-(4Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-diyl)dimethanamine ( 0.22 g, 0.6
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mmol ) in DMF was added drop wise. After stirring at room temperature overnight the
resulting mixture was filtered through celite. The filtrate was concentrated in vacuum.
The residue was dissolved in 50 ml DCM and washed with brine, dried and concentrated
to give 0.521 g crude. Purification by chromatography on silica gel with a DCM/MeOH
(15:1) as eluent gave 0.338 g product as a white solid in 86% yield. 1HNMR (400 MHz,
CDCl3) 8.00 (S, 2H), 7.65 (d, J= 8.40 Hz, 2H), 7.63 (d, J= 7.9 Hz, 2H), 7.22 (d, J= 2.2
Hz, 2H), 7.16 (d, J= 3.1 Hz, 2H), 4.68 (d,d, J= 5.28 Hz, J= 1.6 Hz, 4H), 4.2 (s, 2H), 3.57
(m, 2H), 3.01 (t, 2H), 2.68 (s, 3H), 2.66 (s, 3H), 2.62 (s, 3H), 2.54 (s, 3H), 2.39 (s, 4H),
2.09 (m, 2H).

13

C NMR (400MHz, CDCl3): δ 169.93, 167.40, 167.21, 159.22, 150.21,

148.43, 148.12, 131.36, 130.24, 130.07, 129.46, 129.31, 128.11, 127.74, 127.16, 127.05,
113.83, 113.72, 72.17, 69.45, 55.29, 55.22, 38.75-15.20.

N,N'-((2-(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(4ethylbenzamide)
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The solution of N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(4-ethylbenzamide) (338 mg, 0.5 mmol) in 12 ml EtOH and 6 ml
1N HCl was refluxed for 3 hours. After cooled down, the mixture was concentrated to
remove EtOH. The combined organic layers were washed with brine, dried over
anhydrous Na2SO4, filtered and concentrated to give 0.468 g crude. Purification on silica
gel column with a DCM / MeOH (10:1) solvent system as eluent to give 103 mg white
solid in 40% yield. 1HNMR (400 MHz, CDCl3) 8.2 (br, 1H), 7.98 (d, J= 7.84 Hz, 2H),
7.83 (d, J= 7.84 Hz, 2H), 7.21 (m, 4H), 4.72 (m, 4H), 3.60 (t, 2H), 3.2 (t, 2H), 2.86 (s,
3H), 2.67 (m, 4H), 2.58 (s, 3H), 2.04 (m, 2H). 13C NMR (400MHz, CDCl3): δ 167.71,
167.56, 155.11, 148.42, 130.70, 130.41, 127.87, 127.60, 60.94, 37.55, 31.94, 28.74,
28.06, 18.00, 16.84, 15.17.

6,8-bis((4-ethylbenzamido)methyl)-5,7-dimethyl-2,3-dihydro-1H-indolizin-4-ium
chloride
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Methanesulfonyle chloride (51.3 mg, 0.44 mmol) was added into the solution of N,N'((2-(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(4ethylbenzamide) (103 mg, 0.21 mmol) in 5 ml CH2Cl2 and triethylamine (68 mg,
0.6mmol) at 0°C. The resulting mixture was allowed to warm to room temperature over 1
hour. The mixture was diluted with 5 ml CH2Cl2. The CH2Cl2 layer was washed with 1N
HCl twice followed by brine , dried over Na2SO4, filtered and concentrated. Purification
with chromatography on silica gel with a CH2Cl2/MeOH (10:1) solvent system as the
eluent to give 45 mg pure white solid in 45% yield. 1HNMR (400 MHz, MeOD) 8.8 (s,
1H), 8.6 (s, 1H), 7.98 (d, J= 6.20 Hz, 2H), 7.96 (d, J= 7.1 Hz, 2H), 7.1 (m, 4H), 4.62 (d,d,
J= 5.3 Hz, J= 1.40 Hz, 2H), 3.7 (t, 2H), 2.7 (s, 3H), 2.72 (s, 3H), 2.49 (m, 4H), 2.45 (m,
2H).

13

C NMR (400MHz, MeOD) 167.36 (2 carbons), 158.7, 158.15, 156.20, 150.32-

127.78, 59.19, 39.95, 39.14, 33.107, 21.42, 17.92, 17.62. MS m/z: 470.28

N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(([1,1'-biphenyl]-4-carboxamide))
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On an ice water bath, a solution of p-phenylbenzoic acid (0.433 g , 1.8 mmol) in DMF (
6ml ), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ( 0.586 g, 3 mmol
), hydroxybenzotriaoxazole ( 0.413 g, 3 mmol ), molecular sieve and TEA ( 0.549 g , 5.4
mmol

)

with

N2

protection.

After

20

minutes

a

solution

of

(2-(3-(4-

Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-diyl)dimethanamine (0.25 g, 0.7
mmol ) in DMF was added drop wise. After stirring at room temperature overnight the
resulting mixture was filtered through celite. The filtrate was concentrated in vacuum.
The residue was dissolved in 50 ml DCM and washed with brine, dried and concentrated
to give 0.630 g crude. Purification by chromatography on silica gel with a DCM/MeOH
(15:1) as eluent gave 0.24 g product as a white solid in 40% yield. 1HNMR (400 MHz,
CDCl3) 7.89 (d, J= 8.6 Hz, 2H), 7.79 (d, J= 8.12 Hz, 2H), 7.4 (m, 8H), 7.04 (d, J= 2.1
Hz, 2H), 6.70 (d, J= 8.52 Hz, 2H), 4.72 (d,d, J= 5.9 Hz, J= 2.2 Hz, 4H), 4.2 (s, 2H), 3.7
(s, 3H), 3.52 (t, 2H), 2.01 (m, 2H), 2.61 (s, 3H), 2.56 (s, 3H), 2.02 (m, 2H).

13

C NMR

(400MHz, CDCl3): δ 167.62, 167.40, 159.33, 153.54, 144.43, 144.32, 142.18, 139.95,
132.28, 130.72, 129.60-124.95, 117.85, 113.76, 110.78, 55.21, 38.19, 37.71, 29.96,
29.36, 19.58, 16.52.

N,N'-((2-(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(([1,1'biphenyl]-4-carboxamide))
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The solution of N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(([1,1'-biphenyl]-4-carboxamide)) (240 mg, 0.3 mmol) in 12 ml
EtOH and 6 ml 1N HCl was refluxed for 5 hours. After cooled down, the mixture was
concentrated to remove EtOH. The combined organic layers were washed with brine,
dried over anhydrous Na2SO4, filtered and concentrated to give 680 mg crude.
Purification was done on silica gel column with a DCM / MeOH (10:1) solvent system as
eluent to give 88 mg white solid in 44% yield. 1HNMR (400 MHz, CDCl3) 7.85 (d, J=
7.80 Hz, 2H), 7.83 (d, J= 7.37 Hz, 2H), 7.69 (d, J= 6.40 Hz 2H), 7.6 (d, J= 1.90 Hz 2H),
7.4 (m, 6H), 4.77 (d,d, J= 3.88 Hz, J= 7.04 Hz, 4H), 3.7 (t, 2H), 2.94 (s, 3H), 2.81 (s,
3H), 2.00 (m, 2H).

13

C NMR (400MHz, CDCl3): δ 167.8, 167.92, 155.5, 15535, 144.5,

143.5, 130.2-127.54, 62.45, 39.4, 38.35, 33.85, 18.6, 16.9.

6,8-bis([1,1'-biphenyl]-4-ylcarboxamidomethyl)-5,7-dimethyl-2,3-dihydro-1Hindolizin-4-ium chloride
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Methanesulfonyle chloride (46 mg, 0.4 mmol) was added into the solution of N,N'-((2(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(([1,1'-biphenyl]-4carboxamide)) (88 mg, 0.15 mmol) in 6 ml CH2Cl2 and triethylamine (60 mg, 0.45mmol)
at 0°C. The resulting mixture was allowed to warm to room temperature over 1 hour. The
mixture was diluted with 20 ml CH2Cl2. The CH2Cl2 layer was washed with 1N HCl
twice followed by brine , dried over Na2SO4, filtered and concentrated. Purification was
performede with chromatography on silica gel with a CH2Cl2/MeOH (10:1) solvent
system as the eluent to give 42 mg pure white solid in 46% yield.

1

HNMR (400 MHz,

MeOD) 9.04 (s, 1H), 8.9 (s, 1H), 8.17 (d, J= 8.04 Hz, 2H), 7.5 (m, 8H), 7.38 (m, 6H),
4.7 (d,d, J=3.96 Hz, J= 2.35 Hz, 4H), 3.7 (t, 2H), 2.82 (s, 3H), 2.77 (s, 3H), 2.50 (m,
2H).

13

C NMR (400MHz, MeOD) 167.36 (2 carbons), 158.7, 158.15, 152.32-124.78,

59.19, 39.95, 39.14, 33.107, 21.42, 17.92, 17.62. MS m/z: 566.
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N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(4-isopropylbenzamide)

On an ice water bath, a solution of p-isopropylbenzoic acid (0.358 g , 2.1 mmol) in DMF
( 4ml ), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ( 0.586 g, 3
mmol ), hydroxybenzotriaoxazole ( 0.413 g, 3 mmol ), molecular sieve and TEA ( 0.662g
, 6.3 mmol ) with N2 protection. After 20 minutes a solution of (2-(3-(4Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-diyl)dimethanamine ( 0.2 g, 0.58
mmol ) in DMF was added drop wise. After stirring at room temperature overnight the
resulting mixture was filtered through celite. The filtrate was concentrated in vacuum.
The residue was dissolved in 50 ml DCM and washed with brine, dried and concentrated
to give 0.400 g crude. Purification by chromatography on silica gel with a DCM/MeOH
(15:1) as eluent gave 0.15 g product as a white solid in 86% yield. 1HNMR (400 MHz,
CDCl3) 7.84 (d, J= 8.84 Hz, 2H), 7.74 (d, J= 8.28 Hz, 2H), 7.22 (m, 4H), 7.18 (d, J=
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8.56 Hz, 2H), 6.7 (d, J= 8.6 Hz, 2H), 4.67 (d,d, J= 4.76 Hz, J= 9.2 Hz, 4H), 4.26 (s, 2H),
3.7 (s, 3H), 3.51 (m, 3H), 3.07 (t, 2H), 2.903 (m, 2H), 2.62 (s, 3H), 2.48 (s, 2H), 2.01 (m,
2H). 13C NMR (400MHz, CDCl3): δ 167.55, 167.33, 159.2727, 153.11, 152.82, 131.211214.67, 118.13, 113.71, 110.68, 72.39, 69.25, 55.22, 38.26, 37.73, 34.06, 30.54, 29.45,
23.73, 23.72, 20.50, 16.10.

N,N'-((2-(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(4isopropylbenzamide)

The solution of N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(4-isopropylbenzamide) (400 mg, 0.62 mmol) in 16 ml EtOH and
8 ml 1N HCl was refluxed for 6 hours. After cooled down, the mixture was concentrated
to remove EtOH. The combined organic layers were washed with brine, dried over
anhydrous Na2SO4, filtered and concentrated to give 340 mg crude. Purification was done
on silica gel column with a DCM / MeOH (10:1) solvent system as eluent to give 160 mg
white solid in 51% yield. 1HNMR (400 MHz, CDCl3) 7.79 (d, J= 7.64 Hz, 2H), 7.75 (d,
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J= 8.28 Hz, 2H), 7.13 (d, J= 3.5 Hz 2H), 7.09 (d, J= 1.60 Hz 2H), 4.69 (d, J= 8.64 Hz,
4H), 3.65 (t, 2H), 3.1 (t, 2H), 2.9 (m, 2H), 2.67 (s, 3H), 2.49 (s, 3H), 2.00 (m, 2H).

13

C

NMR (400MHz, CDCl3): δ 167.57, 167.22, 153.04, 129.82, 127.4, 127.31, 126.62,
61.85, 38.25, 37.82, 34.07, 31.29, 23.73, 16.06.

6,8-bis((4-isopropylbenzamido)methyl)-5,7-dimethyl-2,3-dihydro-1H-indolizin-4ium chloride

Methanesulfonyle chloride (73 mg, 0.6 mmol) was added into the solution of N,N'-((2(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(4isopropylbenzamide) (160 mg, 0.3 mmol) in 5 ml CH2Cl2 and triethylamine (94 mg,
0.6mmol) at 0°C. The resulting mixture was allowed to warm to room temperature over 1
hour. The mixture was diluted with 20 ml CH2Cl2. The CH2Cl2 layer was washed with
1N HCl twice followed by brine, dried over Na2SO4, filtered and concentrated.
Purification was done by chromatography on silica gel with a CH2Cl2/MeOH (12:1)
solvent system as the eluent to give 52 mg pure white solid in 41% yield. 1HNMR (400
MHz, MeOD) 8.7 (s, 1H), 8.64 (s, 1H), 7.79 (d, J= 8.1 Hz ,2H), 7.95 (d, J= 8.5 Hz, 2H),
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7.21 (m, 4H), 4.74 (d,d, J= 6.2 Hz, J= 5.8 Hz 4H), 4.65 (m, 2H), 3.66 (t, 2H), 2.76 (m,
2H), 2.76 (s, 3H), 2.67 (s, 3H), 2.59 (s, 3H), 2.48 (m, 2H). 13C NMR (400MHz, MeOD)
167.36 (2 carbons), 158.7, 156.15, 152.32-124.78, 57.19, 39.95, 38.14, 38.39, 33.107,
23.72, 21.42, 17.92, 17.62. MS m/z: 499.

N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(4-methoxybenzamide)

On an ice water bath, a solution of p-methoxybenzoic acid (0.339 g , 2.2 mmol) in DMF (
6ml ), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ( 0.513 g, 2.6
mmol ), hydroxybenzotriaoxazole ( 0.361 g, 2.6 mmol ), molecular sieve and TEA (
0.676g , 6.6 mmol ) with N2 protection. After 20 minutes a solution of (2-(3-(4Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-diyl)dimethanamine ( 0.255 g, 0.7
mmol ) in DMF was added drop wise. After stirring at room temperature overnight the
resulting mixture was filtered through celite. The filtrate was concentrated in vacuum.
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The residue was dissolved in 50 ml DCM and washed with brine, dried and concentrated
to give 0.4 g crude. Purification by chromatography on silica gel with a DCM/MeOH
(15:1) as eluent gave 0.15 g product as a white solid in 90% yield. 1HNMR (400 MHz,
CDCl3) 8.2 (s, 1H), 8.18 (s, 1H), 7.78 (d, J= 7.79 Hz, 2H), 7.69 (d, J= 7.80 Hz, 2H),
7.59 (d, J= 2.96 Hz, 2H), 7.53 (d, 2H), 7.12 (m, 4H), 7.05 (d, 2H), 6.70 (d, 2H), 4.72 (d,d,
J= 2.84 Hz, J= 6.40 Hz, 4H), 4.22 (t, 2H), 3.73 (s, 3H), 3.41 (t, 2H), 3.1 (t, 2H), 2.56 (s,
3H), 2.55 (s, 3H), 2.39 (s, 3H), 2.02 (m, 2H).

13

C NMR (400MHz, CDCl3): δ 169.93,

167.40, 167.21, 159.22, 150.21, 148.43, 148.12, 131.36, 130.24, 130.07, 129.46, 129.31,
128.11, 127.74, 127.16, 127.05, 113.83, 113.72, 72.17, 69.45, 55.29, 55.22, 38.75-15.20.

N,N'-((2-(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(4methoxybenzamide)
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The solution of N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(4-methoxybenzamide) (400 mg, 0.6 mmol) in 16 ml EtOH and 8
ml 1N HCl was refluxed for 6 hours. After cooled down, the mixture was concentrated to
remove EtOH. The combined organic layers were washed with brine, dried over
anhydrous Na2SO4, filtered and concentrated to give 491.58 mg crude. Purification was
done on silica gel column with a DCM / MeOH (10:1) solvent system as eluent to give
120 mg white solid in 40% yield. 1HNMR (400 MHz, CDCl3) 7.93 (m, 4H), 7.44 (m,
5H), 4.76 (m, 4H), 3.67 (t, 2H), 3.23 (t, 2H), 2.68 (s, 3H), 2.57 (s, 3H), 2.35 (s, 3H), 2.04
(m, 2H). 13C NMR (400MHz, CDCl3): δ 167.61, 167.56, 154.11, 147.42, 133.50, 133.42,
128.87, 127.60, 60.94, 37.55, 31.94, 28.74, 28.06, 18.00, 16.84, 15.17.

6,8-bis((4-methoxybenzamido)methyl)-5,7-dimethyl-2,3-dihydro-1H-indolizin-4-ium
chloride
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Methanesulfonyle chloride (54 mg, 0.4 mmol) was added into the solution of N,N'-((2(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(4methoxybenzamide) (120 mg, 0.2 mmol) in 5 ml CH2Cl2 and triethylamine (74 mg,
0.7mmol) at 0°C. The resulting mixture was allowed to warm to room temperature over 1
hour. The mixture was diluted with 20 ml CH2Cl2. The CH2Cl2 layer was washed with
1N HCl twice followed by brine, dried over Na2SO4, filtered and concentrated.
Purification was done using chromatography on silica gel with a CH2Cl2/MeOH (10:1)
solvent system as the eluent to give 53 mg pure white solid in 80% yield. 1HNMR (400
MHz, MeOD) 7.78 (d, , J= 3.56 Hz, 2H), 7.75 (d, , J= 3.56 Hz, 2H), 6.96 (d, , J= 4.52
Hz, 2H), 6.94 (d, , J= 4.7 Hz, 2H), 4.87 (d,d, J= 4.84 Hz,, J= 6.4 Hz, 2H), 4.66 (s, 2H),
3.82 (s,63H), 3.77 (t, 2H), 2.85 (s, 3H), 2.69 (s, 3H), 2.49 (m, 2H).

13

C NMR (400MHz,

MeOD) 167.6 (2 carbons), 158.7, 158.15, 152.32-124.78, 58.19, 37.95, 37.14, 33.107,
21.42, 17.92, 16.62. MS m/z: 474.24. MS m/z: 482.14

N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(4-bromobenzamide)
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On an ice water bath, a solution of p-bromobenzoic acid (0.439 g , 2.1 mmol) in DMF (
8ml ), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ( 0..502 g, 2.6
mmol ), hydroxybenzotriaoxazole ( 0.354 g, 2.6 mmol ), molecular sieve and TEA (
0.662 g , 6.5 mmol ) with N2 protection. After 20 minutes a solution of (2-(3-(4Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-diyl)dimethanamine ( 0.25 g, 0.7
mmol ) in DMF was added drop wise. After stirring at room temperature overnight the
resulting mixture was filtered through celite. The filtrate was concentrated in vacuum.
The residue was dissolved in 50 ml DCM and washed with brine, dried and concentrated
to give 0.68 g crude. Purification by chromatography on silica gel with a DCM/MeOH
(15:1) as eluent gave 0.438 g product as a white solid in 85% yield. 1HNMR (400 MHz,
CDCl3) 7.92 (d, J= 8.84 Hz, 2H), 7.90 (d, J= 8.28 Hz, 2H), 7.75 (m, 4H), 7.72 (d, J=
8.56 Hz, 2H), 6.99 (d, J= 8.6 Hz, 2H), 6.91 (d, 2H), 4.47 (d,d, J= 4.76 Hz, J= 9.2 Hz,
4H), 4.38 (s, 2H), 3.83 (s, 3H), 3.01 (t, 2H), 2.95 (m, 2H), 2.52 (s, 3H), 2.38 (s, 2H), 2.01
(m, 2H).

13

C NMR (400MHz, CDCl3): δ 167.8, 167.33, 155.27, 153.11, 152.82, 131.7,
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214.67, 118.13, 113.71, 110.68, 72.39, 69.25, 55.22, 38.26, 37.73, 34.06, 30.54, 29.45,
23.73, 23.72, 20.50, 16.10.

N,N'-((2-(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(4bromobenzamide)

The solution of N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(4-bromobenzamide) (420 mg, 0.6 mmol) in 18 ml EtOH and 9
ml 1N HCl was refluxed for 5 hours. After cooled down, the mixture was concentrated to
remove EtOH. The combined organic layers were washed with brine, dried over
anhydrous Na2SO4, filtered and concentrated to give 545 mg crude. Purification was done
on silica gel column with a DCM / MeOH (10:1) solvent system as eluent to give 155 mg
white solid in 52% yield. 1HNMR (400 MHz, CDCl3) 7.92 (d, J= 7.94 Hz, 2H), 7.82 (d,
J= 8.24 Hz, 2H), 7.56 (d, J= 2.5 Hz 2H), 7.55 (d, J= 1.60 Hz 2H), 4.71 (d, J= 8.64 Hz,
4H), 3.3 (t, 2H), 3.12 (m, 2H), 2.77 (s, 3H), 2.69 (s, 3H), 2.09 (m, 2H).

13

C NMR

(400MHz, CDCl3): δ 167.87, 167.72, 154.04, 153.89 129.82, 125.4, 125.31, 124.62,
60.85, 38.5, 37.82, 34.07, 31.29, 23.73, 16.05.
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6,8-bis((4-bromobenzamido)methyl)-5,7-dimethyl-2,3-dihydro-1H-indolizin-4-ium
chloride

Methanesulfonyle chloride (60.1mg, 0.52 mmol) was added into the solution of N,N'-((2(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(4-bromobenzamide)
(0.155 mg, 0.26 mmol) in 6 ml CH2Cl2 and triethylamine (79.1 mg, 0.78mmol) at 0°C.
The resulting mixture was allowed to warm to room temperature over 1 hour. The
mixture was diluted with 25 ml CH2Cl2. The CH2Cl2 layer was washed with 1N HCl
twice followed by brine , dried over Na2SO4, filtered and concentrated. Purification was
performed on chromatography on silica gel with a CH2Cl2/MeOH (10:1) solvent system
as the eluent to give 46 mg pure white solid in 30% yield. 1HNMR (400 MHz, MeOD)
7.82 (d, , J= 8.4 Hz, 2H), 7.79 (d, J= 7.94 Hz 2H), 7.36 (d, 2H), 7.33 (d, J= 2.04 Hz 2H),
4.73 (d,d, J= 2.3 Hz, J= 6.2 Hz 4H), 3.75 (t, 2H), 3.48 (s, 2H), 3.16 (m, 2H), 2.62 (s,
3H), 2.5 (s, 3H), 2.03 (m, 2H).

13

C NMR (400MHz, MeOD) 167.36 (2 carbons), 158.7,

156.15, 152.32-124.78, 60.19, 39.8, 39.14, 34.107, 21.56, 17.89, 16.2. MS m/z: 570.04.
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N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(4-chlorobenzamide)

On an ice water bath, a solution of p-chlorobenzoic acid (0.342 g , 2.1 mmol) in DMF (
6ml ), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ( 0.502 g, 2.6
mmol ), hydroxybenzotriaoxazole ( 0.354 g, 2.6 mmol ), molecular sieve and TEA (
0.66g , 6.5 mmol ) with N2 protection. After 20 minutes a solution of (2-(3-(4Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-diyl)dimethanamine ( 0.22 g, 0.6
mmol ) in DMF was added drop wise. After stirring at room temperature overnight the
resulting mixture was filtered through celite. The filtrate was concentrated in vacuum.
The residue was dissolved in 50 ml DCM and washed with brine, dried and concentrated
to give 0.648 g crude. Purification by chromatography on silica gel with a DCM/MeOH
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(15:1) as eluent gave 0.306 g product as a white solid in 68% yield. 1HNMR (400 MHz,
CDCl3) 7.97 (d, J= 7.84 Hz, 2H), 7.96 (d, J= 7.28 Hz, 2H), 7.76 (m, 4H), 7.75 (d, J= 8.1
Hz, 2H), 6.98 (d, J= 8.6 Hz, 2H), 6.86 (d, 2H), 4.78 (d,d, J= 2.7 Hz, J= 6.5 Hz, 4H), 4.68
(s, 2H), 3.97 (s, 3H), 3.33 (t, 2H), 2.85 (m, 2H), 2.72 (s, 3H), 2.38 (s, 2H), 2.01 (m, 2H).
13

C NMR (400MHz, CDCl3): δ 167.8, 167.33, 155.27, 153.11, 152.82, 131.7, 214.67,

118.13, 113.71, 110.68, 72.39, 69.25, 55.22, 38.26, 37.73, 34.06, 30.54, 29.45, 23.73,
23.72, 20.50, 16.10.

N,N'-((2-(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(4chlorobenzamide)

The solution of N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(4-chlorobenzamide) (306 mg, 0.2 mmol) in 12 ml EtOH and 6 ml
1N HCl was refluxed for 5 hours. After cooled down, the mixture was concentrated to
remove EtOH. The combined organic layers were washed with brine, dried over
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anhydrous Na2SO4, filtered and concentrated to give 423 mg crude. Purification was done
on silica gel column with a DCM / MeOH (10:1) solvent system as eluent to give 125 mg
white solid in 51% yield. 1HNMR (400 MHz, CDCl3) 7.83 (m, 4H), 7.24 (m, 5H), 4.76
(m, 4H), 3.67 (t, 2H), 3.1 (t, 2H), 2.69 (s, 3H), 2.57 (s, 3H), 2.35 (s, 3H), 2.04 (m, 2H).

6,8-bis((4-chlorobenzamido)methyl)-5,7-dimethyl-2,3-dihydro-1H-indolizin-4-ium
chloride

Methanesulfonyle chloride (56 mg, 0.48 mmol) was added into the solution of N,N'-((2(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(4-chlorobenzamide)
(125 mg, 0.2 mmol) in 5 ml CH2Cl2 and triethylamine (75 mg, 0.75mmol) at 0°C. The
resulting mixture was allowed to warm to room temperature over 1 hour. The mixture
was diluted with 25 ml CH2Cl2. The CH2Cl2 layer was washed with 1N HCl twice
followed by brine , dried over Na2SO4, filtered and concentrated. Purification was
performed with chromatography on silica gel with a CH2Cl2/MeOH (10:1) solvent system
as the eluent to give 48 mg pure white solid in 40% yield. 1HNMR (400 MHz, MeOD)
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7.8 (d, J= 8.04 Hz, 2H), 7.78 (d, J= 8.64 Hz, 2H), 7.46 (d, J= 3.04 Hz, 2H), 7.43 (d, 2H),
4.82 (d,d, J= 3.65 Hz, J= 6.04 Hz, 4H), 4.68 (s, 2H), 3.78 (t, sH), 2.86 (s, 3H), 2.78 (s,
3H), 2.5 (m, 2H).

13

C NMR (400MHz, MeOD) 167.82, 167.75, 158.3, 158.1, 152.2,

150.51, 134.36, 131.13, 130.70, 130.67, 127.94, 126, 126, 126.36, 124.8, 59.9, 39.5, 39.4,
33.1, 21.2, 17.2, 17.2. MS m/z: 482.14.

N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(4-nitrobenzamide)

On an ice water bath, a solution of p-nitrobenzoic acid (0.876 g , 5.2 mmol) in DMF (
4ml ), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ( 1.206 g, 6.2
mmol ), hydroxybenzotriaoxazole ( 0.495 g, 6.2 mmol ), molecular sieve and TEA (
1.59g , 15.7 mmol ) with N2 protection. After 20 minutes a solution of (2-(3-(4Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-diyl)dimethanamine ( 0.600 g, 1.7
mmol ) in DMF was added drop wise. After stirring at room temperature overnight the
resulting mixture was filtered through celite. The filtrate was concentrated in vacuum.
The residue was dissolved in 50 ml DCM and washed with brine, dried and concentrated
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to give 1.5 g crude. Purification by chromatography on silica gel with a DCM/MeOH
(15:1) as eluent gave 645 mg product as a white solid in 85% yield. 1HNMR (400 MHz,
CDCl3) 7.8 (d, J= 8.6 Hz, 2H), 7.78 (d, J= 8.12 Hz, 2H), 7.65 (d, 4H), 7.03 (d, J= 2.1
Hz, 2H), 6.70 (d, J= 8.52 Hz, 2H), 4.72 (d,d, J= 5.9 Hz, J= 2.2 Hz, 4H), 4.2 (s, 2H), 3.7
(s, 3H), 3.52 (t, 2H), 2.01 (m, 2H), 2.61 (s, 3H), 2.56 (s, 3H), 2.02 (m, 2H).

13

C NMR

(400MHz, CDCl3): δ 167.62, 167.40, 159.33, 153.54, 144.43, 139.95, 132.28, 129.60124.95, 117.85, 113.76, 110.78, 55.21, 38.19, 37.71, 29.96, 29.36, 19.58, 16.52.

N,N'-((2-(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(4nitrobenzamide)

The solution of N,N'-((2-(3-((4-methoxybenzyl)oxy)propyl)-4,6-dimethylpyridine-3,5diyl)bis(methylene))bis(4-nitrobenzamide) (1.1 mg, 1.7 mmol) in 60 ml EtOH and 30 ml
1N HCl was refluxed for 6 hours. After cooled down, the mixture was concentrated to
remove EtOH. The combined organic layers were washed with brine, dried over
anhydrous Na2SO4, filtered and concentrated to give 1.5g crude. Purification was done on
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silica gel column with a DCM / MeOH (10:1) solvent system as eluent to give 659 mg
white solid in 73% yield1HNMR (400 MHz, CDCl3) 7.85 (d, J= 7.80 Hz, 2H), 7.83 (d, J=
7.37 Hz, 2H), 7.68 (d, J= 6.40 Hz, 2H), 7.63 (d, J= 1.90 Hz, 2H), 4.75 (d,d, J= 3.88 Hz,
J= 7.04 Hz, 4H), 3.72 (t, 2H), 2.96 (s, 3H), 2.83 (s, 3H), 2.05 (m, 2H).

13

C NMR

(400MHz, CDCl3): δ 167.8, 167.92, 155.5, 155.35, 144.5-127.54, 62.45, 39.4, 38.35,
33.85, 18.6, 16.9.
5,7-dimethyl-6,8-bis((4-nitrobenzamido)methyl)-2,3-dihydro-1H-indolizin-4-ium
chloride

Methanesulfonyle chloride (288 mg, 2.5 mmol) was added into the solution of N,N'-((2(3-hydroxypropyl)-4,6-dimethylpyridine-3,5-diyl)bis(methylene))bis(4-nitrobenzamide)
(657 mg, 1.2 mmol) in 38 ml CH2Cl2 and triethylamine (382 mg, 3.7mmol) at 0°C. The
resulting mixture was allowed to warm to room temperature over 1 hour. The mixture
was diluted with 50 ml CH2Cl2. The CH2Cl2 layer was washed with 1N HCl twice
followed by brine , dried over Na2SO4, filtered and concentrated. Purification was done
by chromatography on silica gel with a CH2Cl2/MeOH (10:1) solvent system as the
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eluent to give 421 mg pure white solid in 6.2% yield. 1HNMR (400 MHz, MeOD) 7.70
(d, J= 8.2 Hz, 2H), 7.69 (d, J= 8.04 Hz, 2H), 7.61 (d, J= 2.05 Hz, 2H), 7.59 (d, J= 2.12
Hz, 2H), 4.82 (m, 4H), 4.79 (t, 4H), 4.67 (s, 2H), 3.7 (t, 2H), 2.87 (s, 3H), 2.79 (s, 3H),
2.5 (m, 2H).

13

C NMR (400MHz, MeOD) 170.36 (2 carbons), 158.7, 158.15, 152.32-

124.78, 59.19, 39.95, 39.14, 33.107, 21.42, 17.92, 17.62.

13

C NMR (400MHz, MeOD)

1670.3 (2 carbons), 158.7, 152.32-124.78, 59.19, 39.95, 39.14, 33.107, 21.42, 17.92,
17.62. MS m/z: 570.04

6,8-bis((4-aminobenzamido)methyl)-5,7-dimethyl-2,3-dihydro-1H-indolizin-4-ium
chloride

A mixture of 5,7-dimethyl-6,8-bis((4-nitrobenzamido)methyl)-2,3-dihydro-1H-indolizin4-ium chloride (81 mg, 0.15 mmol), Pd/C (10 mg, 10% by weight) and conc. HCl in
MeOH (10 mL) was hydrogenated under 57 psi H2 for 6 hours. The mixture was filtered
through celite to remove Pd/C and concentrated to remove MeOH. Purification was done
by performing chromatography in DCM/MeOH (5:1) system to give 6,8-bis((4aminobenzamido)methyl)-5,7-dimethyl-2,3-dihydro-1H-indolizin-4-ium chloride
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(65 mg, 85% yield) as a white solid. 1HNMR (400 MHz, MeOD) 8.29 (d, J= 8.8 Hz,
2H), 8.27 (d, J= 3.3 Hz, 2H), 8.02 (d, J= 3.3 Hz, 2H), 7.59 (d, J= 8.7 Hz, 2H), 4.80 (m,
4H), 4.72 (t, 4H), 3.81 (s, 2H), 2.89 (s, 3H), 2.82 (s, 3H), 2.54 (m, 2H).

13

C NMR

(400MHz, MeOD) 170.36 (2 carbons), 158.7, 158.15, 152.32-124.78, 59.19, 39.95,
39.14, 33.107, 21.42, 17.92, 17.62.

13

C NMR (400MHz, MeOD) 167.8, 167.78, 153.56,

153.01, 150.9, 150.3, 143.4, 143.2-124.78, 57.19, 40.95, 39.14, 34.107, 22.42, 16.92,
16.62. MS m/z: 444.

5.2 Biological Screening

5.2.1 Anti-proliferation assay
A. Cell culturing:
The CCR5 antagonists were tested on three prostate cancer cell lines – PC-3, DU145 and M12. All the cell lines were incubated at 370C and 5% CO2. The media used to
grow the cells was made of RPMI1640 (500 mL), 1% L-glutamine, 0.1% ITS (5 µg/mL
insulin, 5 µg/mL transferin, 5 µg/mL selenium), 0.1% gentamycin and 10% fetal bovine
serum (FBS). The media used for M12 cell lines contained only 5% FBS and 0.1%
geneticin. After 24 hours of incubation of the M12 cells, the media was replaced with
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serum free media containing 0.1% epidermal growth factor (EGF). PC-3 and DU-145 had
the same media composition containing 0.1% gentamicin.
B. Anti-Proliferation Assay protocol:
On the first day, all the three cell lines were plated in 96 well plates. The number
of cells plated in each well was a fixed number of 1000. The cells were plated in a 100μl
of total media. All the cells were incubated for 24 hours at 37°C and 5% CO2. On the
second day, after 24 hours, the drug solutions of different concentrations were aliquoted
out into each well. The drug dilutions were prepared in phosphate buffer solution (PBS).
PBS and DMSO solution was used as a negative control. The percentage of DMSO used
was the amount that was present in the highest concentration of drug tested. 50 µL of
drug solution was added to each well. The cells were incubated with the drug solution for
72 hours. On the fifth day, the media, PBS and drug solutions were dumped out from the
plate. This was followed by the addition of 100 µL of serum free media with 10% of antiproliferative reagent WST-1. The plates were incubated for 3 hours. The absorbance was
then measured at 450 nM on Flex station 3.The software Prism was used to obtain the
IC50 values of the drugs.
5.2.2 Cytotoxicity assay
A. Cell culturing:
NIH3T3 cells were used to perform the cytotoxicity assay. They were cultured in
in DMEM (Invitrogen 11995065) media which contains 4,500 mg/L D-glucose, L-
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glutamine, and 110 mg/L sodium pyruvate. 10% New Born Calf Serum was used along
with penicillin and streptomycin as antibiotics. They were grown in 8% CO2 and 37°C.
B. Assay protocol:
NIH3T3 cells are plated into 96-well plate in a 100 μl cell solution volume. An
equal amount of 2,000,000 are plated into each well. The control wells do not get any
cells. After 24 hours, the culture media is dumped out and immediately 50 μl of 10%
fresh and warm media is added into each well. To the drug wells, 50 μl of 2x
concentrated drug solutions is added. The negative wells get 50 μl of just media. After 72
hours, WST-1 dye is prepared and old media is dumped out again. Each well is carefully
rinsed with 200 μl HBSS. After rinsing, 200 μl of the WST-1 media is added and
incubated for 3 hours. After the incubation period, WST-1 media is removed from the
wells and another round of rinsing is carried out. After 5 mins, reading is taken at 540 nm
wavelength using blank as the reference.

5.2.2 Calcium mobilization assay
MOLT-4 cell line was used to perform this assay. The assay buffer which
comprised of 25 mL HBBS and 0.5 mL HEPES was used to prepare the drug dilutions of
various concentrations. 50 µL of drug solutions was added to each well. This was
followed by the addition of MOLT-4 cells which were plated in a concentration of 80 µL
per well. The cells along with the drug were incubated for 60 minutes at 37 0C. The
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reaction buffer which comprised of 5 mL of assay buffer, 100 µL probenecid, and 40 µL
Fluo-4 dye was prepared. 50 µL of the reaction buffer was added to the wells followed by
incubation for 60 minutes at 370C.
The stock solution of the agonist RANTES was prepared by adding 25 µL of the
RANTES stock solution and 2.475 mL assay buffer. The RANTES solution was added to
all wells except the blank cells, to which only assay buffer was added. The Flex station
was used to add RANTES and assay buffer to the wells. The fluorescence emission signal
was recorded by the Flex station. The software Prism was used to obtain the IC50 values
of the antagonists.
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6. CONCLUSION

Due to increasing number of cases of prostate cancer every year, and few options
for treatment of the advanced stage of disease, it has become imperative to develop new
anti-prostate cancer therapeutics. By investigating the role of inflammation and its
network in cancer cells, research groups managed to identify overexpression of CCR5 in
PCa cell lines. Due to its implication in many other diseases apart from cancer, this
receptor became an important target to develop drugs against. Many compounds were
identified through high throughput screening. However only a few managed to reach
clinical trials and only one– Maraviroc, managed to clear them to reach market. This
necessitated the discovery of a novel lead compound that would provide with a fresh
perspective on designing an effective antagonist.
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Anibamine, a natural CCR5 antagonist that was isolated in 2004 for its antimicrobial properties was found to have the required novel skeleton to develop a new line
of drugs. It competed for binding with
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I-gp120, the HIV viral envelope protein to

human CCR5 with an IC50 of 1µM. The main objective of this project was to use the
correlation between CCR5 and prostate cancer to develop new line of drugs based on
anibamine. Using this compound as the lead, ten analogues were designed and
synthesized. From the total synthesis of anibamine, a new route was designed to
accommodate the changes required in the structure.
Intermediate 6 was synthesized using two different schemes. Following that
intermediate 14 was prepared at which point the original route deviated to give ten
different analogues with a modified side chain as compared to the original lead. Their
biological screening was performed to test their ability to inhibit proliferation of PCa cell
lines, their cytoxicity and their binding to the receptor.
Anti-proliferation data showed to us that these compounds were more sensitive to
DU-145 cell line as compared to PC-3 and M12. Compound 18d was found to inhibit the
proliferation maximum in all the three cell lines. Apart from that among all the
compounds 18a was another compound to cause relatively better inhibition of
proliferation. Compounds having a more electronic substitution did not show good
inhibition. This proved to us that increasing the polarity in the side chain seemed to
decrease the activity of the compound, whereas having a more lipophilic and bulky group
was necessary for a better activity. Also since the compound that showed maximum

126

activity had a chain length closest to the length of the original compound, it was
important to maintain the chain length for the activity. Majority of the compounds, save
for a few, displayed low toxicity towards normal cells. Out of the compounds that were
tested for their inhibition of calcium mobilization, all of them exhibited good antagonistic
ability in presence of RANTES with 18a displaying the best results.
Although a new lead could not be generated due to limited number of analogues,
these studies formed a benchmark to further carry on a thorough exploration into the
structure activity profile of anibamine. These data along with future modeling studies will
help us in designing the third generation of anibamine analogues that will be successful in
generating a new lead with a higher potency and a better therapeutic profile.
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